Methods and compositions for the treatment of fibrosis-related diseases of the liver

LPAR1 antagonists effectively treat cholangiopathies by inhibiting lipid accumulation and cytokine activity, reducing bile duct damage and inflammation, addressing the lack of effective treatments for these conditions.

WO2026241105A1PCT designated stage Publication Date: 2026-11-19EPIGEN BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027494
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-10
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current therapies are inadequate for halting the progression of cholangiopathies, particularly bile duct and liver damage, as there are no FDA-approved treatments that effectively modulate cytokine signaling pathways and extracellular matrix remodeling to address inflammation and fibrosis-related diseases.

Method used

The use of lysophosphatidic acid receptor subtype 1 selective (LPAR1) antagonists, such as compounds of Formula I and their pharmaceutically acceptable salts, to inhibit lipid accumulation and cytokine activity, thereby treating cholangiopathies like primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and biliary atresia (BA).

Benefits of technology

LPAR1 antagonists demonstrate dose-dependent reduction in bile duct damage and portal inflammation, providing a therapeutic benefit in preclinical models by modulating immune cell recruitment and liver fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027494_19112026_PF_FP_ABST
    Figure US2026027494_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein are methods for the treatment of cholangiopathies, including primary biliary cholangitis, primary sclerosing cholangitis and biliary atresia and related condtions, in particular, primary biliary cholangitis (PBC), comprising administering an effective amount of a selective antagonist of a lysophosphatidic acid receptor subtype 1 (LPAR1) to a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PATENT Docket No. EPN-AC-500PC

[0002] TITLE

[0003] Methods and Compositions For the Treatment of Fibrosis- Related Diseases of the Liver

[0004] STATEMENT OF GOVERNMENT INTEREST

[0005] [1] This invention was made with government support under Grant R43DK134242 awarded by the National Institutes of Health. The US government has certain rights in the invention.

[0006] CROSS-REFERENCE TO RELATED APPLICATIONS

[0007] [2] This international application claims right of priority to pending US Provisional Appl. Ser. No. 63 / 804,298, filed May 12, 2025, the contents of which are incorporated herein in its entirety for all purposes.

[0008] FIELD OF THE INVENTION

[0009] [3] The present invention relates to compounds and compositions having pharmacological activity, and to their use in therapy and prophylaxis of inflammatory and fibrosis-related diseases or conditions in a subject, in particular for human and veterinarian treatments of cholangiopathies, in particular primary biliary cholangitis.

[0010] BACKGROUND OF THE INVENTION

[0011] [4] Imbalances in bioactive lipids lead to detrimental effects on health including bile acid and liver dysfunctions that lead to cholangiopathies. Those imbalances cause lipid accumulation in bile duct and liver, with inflammation, cholangiocyte injury, and fibrosis. Cholangiopathies are a diverse group of disorders that affect the bile ducts and cholangiocytes (bile duct lining cells). Among those, primary biliary cholangitis (PBC), is a chronic disease in which the small bile ducts in the liver become injured, inflamed and eventually destroyed. Primary sclerosing cholangitis (PSC) is a rare disease which originates in the bile ducts and progresses to cause liver damage. Here, inflammation occurring in the bile duct leads to fibrosis and scarring that causes the bile ducts to harden, which eventually leads to liver damage. In biliary atresia (BA), inflammatory and fibrosclerosing of bile ducts results in obliteration of the biliary tracts, which leads to progressive liver damage. Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process following pharmacological or physical injury. Sclerosis is the scarring of tissue which results from these processes.

[0012] PATENT Docket No. EPN-AC-500PC

[0013] Excessive fibrosis more likely than not leads to organ dysfunction and thereby diseases of the affected organs as exemplified herein for the bile duct and liver.

[0014] [5] Cytokines are small cell-signaling protein molecules that are secreted by numerous cell types and are a category of signaling molecules used extensively in intercellular communication. Several cytokines and signaling pathways mediate the fibrogenic process, directly and / or indirectly through pro-inflammatory signaling.

[0015] Bioactive lipids when over-produced above normally regulated levels contribute to lipid accumulation, inflammation and fibrosis-related or fibrosis-mediated disease either by triggering cytokine-mediated signaling or extracellular matrix remodeling.

[0016] [6] Currently, there are no FDA approved therapies directed to the treatment of cholangiopathies that halt disease progression, in particular damage to bile ducts and hence liver. Therefore, there is a need in the art for pharmaceutic compositions or treatment methods that modulate multiple cytokine signaling pathways and / or extracellular matrix remodeling for effectively treating inflammation and fibrosis-related or fibrosis-mediated diseases such as cholangiopathies. Pharmaceutical compositions and treatment methods described herein solve that problem in the art by combining compositions or therapeutic treatments that modulate cytokine signaling pathways and / or extracellular matrix remodeling directly related to bile duct damage. Those combined treatments provide unexpected benefit with respect to each other in the treatment of the aforementioned fibrosis-related or fibrosis-mediated diseases of the bile duct and liver.

[0017] SUMMARY OF THE INVENTION

[0018] [7] Disclosed herein are methods that inhibit the physiological activity of lipids and certain cytokines and are therefore useful for the treatment or prevention of diseases involving fibrosis of the bile duct and liver, in which modulation of bioactive lipid accumulation and / or inhibition of the physiological activity of cytokines is believed to underlie the mechanism for their effectiveness.

[0019] [8] Among the methods disclosed herein are methods for the use of lysophosphatidic acid receptor subtype 1 selective (LPAR1) antagonists for the treatment of cholangiopathies, which have been unexpectedly found to be useful for the treatment of these diseases, in particular primary biliary cholangitis (PBC).

[0020] [9] In each of the forgoing aspects the LPAR1 antagonist includes compounds of

[0021] Formula I that have the structure:

[0022] PATENT Docket No. EPN-AC-500PC

[0023]

[0024] Formula I,

[0025] or a salt thereof, in particular, a pharmaceutically acceptable salt,

[0026]

[0010] wherein RAis -CO2H, -CO2RB, -CN, tetrazolyl, -C(=O)NH2, -C(=O)NHRB,

[0027] -C(=O)NHSO2RBor -C(=O)NHCH2CH2SO3H or has the structure;

[0028]

[0029]

[0011]

[0030]

[0031]

[0012] RBis substituted or unsubstituted C1-C4 alkyl or has the structure of one of

[0032]

[0033]

[0013] L1is substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted Cr

[0034] C6fluoroalkylene, substituted or unsubstituted C3-C8cycloalkylene, substituted or unsubstituted Ci-C6heteroalkylene;

[0035]

[0014] wherein A1is -N= or -CH;

[0036]

[0015] wherein Ring A has the structure of:

[0037]

[0038]

[0016]

[0039]

[0017] wherein Rcis -CN, -F, -Cl, -Br, -I, -OC1-C4 alkyl, C3-C6cycloalkyl, or C1-C4 fluoroalkyl;

[0040]

[0018] and RDis -N(RF)-C(=O)XCH(RG)-CY, wherein X is O and CY is unsubstituted phenyl or phenyl substituted with one or more RH, in particular one RH:

[0041] PATENT Docket No. EPN-AC-500PC

[0042]

[0043]

[0019] RE, RFand RGindependently are -H or C1-C4 alkyl or C3-Cs cycloalkyl or REand RFindependently are -H or C1-C4 alkyl or Ci-C6cycloalkyl and RGis -C1-C4 alkyl and is taken together with one of the RHphenyl moieties, if present, and the carbon atom to which RGand said phenyl moiety are attached to define a substituted or unsubstituted 5 or 6-membered carbocycle or a substituted or unsubstituted 5 or 6-membered heterocycle;

[0044]

[0020] RHis absent or is independently halogen, -CN, -NO2, -OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, or C1-C4 alkoxy, in particular halogen, preferably -F or -Cl.

[0045]

[0021] Other compounds of Formula I in the invention have the structures or names indicated by the numbered embodiments described herein.

[0046]

[0022] In other aspects of the invention, the LPAR1 antagonist is selected from the group consisting of BMS-986278, which is (1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1 H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1 -carboxylic acid, SAR-100842, which is 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1 H-indene-2-carboxylic acid, PIPE-791, which is trans-4-(3-(2-(difluoromethoxy)-6-methoxypyridin-3-yl)-1 -(2-isopropylphenyl)ureido)cyclohexane-1 -carboxylic acid, ACT-1016-0707, which is N-(6-chloro-4-methoxypyridin-3-yl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide, LTSE-2578, CTX-343 and salts thereof.

[0047]

[0023] In a preferred aspect of the invention the LPAR1 antagonist is (R)-1 -phenylethyl (4-chloro-1-(4'-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1, T-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate or a salt thereof or is (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1 -yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid or a salt thereof.

[0048]

[0024] In a preferred aspect the methods described herein are useful for the treatment of cholangiopathies.

[0049] PATENT Docket No. EPN-AC-500PC

[0050]

[0025] In another preferred aspect of the invention, the methods described herein are suitable for the treatment of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and biliary atresia (BA).

[0051]

[0026] In a still other preferred aspects, the methods described herein are suitable for the treatment of primary biliary cholangitis (PBC).

[0052]

[0027] Other methods of the invention have the structures indicated by the numbered embodiment and claims herein.

[0053] BRIEF DESCRIPTION OF THE DRAWINGS

[0054]

[0028] Features of the present disclosure will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. It will be understood that these drawings depict only certain embodiments in accordance with the disclosure and, therefore, are not to be considered limiting of its scope; the disclosure will be described with additional specificity and detail through use of the accompanying drawings. An apparatus, system or method according to some of the described embodiments sometimes have several aspects, no single one of which necessarily is solely responsible for the desirable attributes of the apparatus, system or method. After considering this discussion, and particularly after reading the section entitled “Detailed Description of the Invention” one of ordinary skill in the relevant art will understand how illustrated features serve to explain certain principles of the present disclosure.

[0055]

[0029] FIGURE 1 shows the activity of a Formula I compound of example 2 for the inhibition of RAW macrophage migration (IC5o-2.1 nM, p < 0.0001), demonstrating that LPAR1 antagonists modulate immune cell recruitment and hence inflammation.

[0056]

[0030] FIGURE 2 shows the activity of a Formula I compound of example 1 for the inhibition of human liver stellate cell proliferation [p < 0.01 compared to LPA alone], demonstrating that LPAR1 antagonists modulate proliferative events leading to liver fibrosis.

[0057]

[0031] FIGURE 3 shows a table of pharmacokinetic parameters for selected examples of a Formula 1 compound at a single dose of 20mg / Kg, of which example 2 demonstrates preferred oral exposure.

[0058]

[0032] FIGURE 4 shows a study design for the therapeutic evaluation of a compound of Formula 1 in the ARE del / _preclinical model of PBC. Mice are maintained for 12 weeks until the establishment of a disease phenotype. With this design mice received either vehicle control (n=7), example 2 at either 10mg / Kg / day (n=6) or 20mg / Kg / day (n=7).

[0059] PATENT Docket No. EPN-AC-500PC

[0060]

[0033] FIGURE 5 shows the efficacy of example 2 in the ARE del / _preclinical model of PBC after disease was established (12 weeks), in which animals were treated orally with either low dose (L) of 10mg / Kg / day (n=6) or high dose (H) of 20mg / Kg / day (n=7). H& E liver stains at 24 weeks demonstrate that both doses statistically inhibit bile duct damage compared to vehicle (p < 0.05). A dose dependent reduction in portal inflammation was observed. A statistical inhibition of portal inflammation was observed for example 2 at 20mg / Kg / day compared to vehicle (p < 0.05).

[0061] DETAILED DESCRIPTION OF THE INVENTION

[0062]

[0034] Definitions

[0063]

[0035] As used herein and unless otherwise stated or implied by context, terms that are used herein have the meanings defined below. Unless otherwise contraindicated or implied, e g., by including mutually exclusive elements or options, in these definitions and throughout this specification, the terms "a" and "an" mean one or more and the term "or" means “and / or” where permitted by context. Thus, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise.

[0064]

[0036] At various locations in the present disclosure, e.g., in any disclosed embodiments or in the claims, reference is made to compounds, compositions, compositions, or methods that “comprise” one or more specified components, elements or steps. Invention embodiments also specifically include those compounds, compositions, compositions or methods that are or that consist of or consist essentially of those specified components, elements or steps. The terms "comprising", "consist of" and "consist essentially of" have their normally accepted meanings under U. S. patent law unless otherwise specifically stated. The term “comprised of” is used interchangeably with the term “comprising” and are stated as equivalent terms. For example, disclosed compositions, devices, articles of manufacture or methods that "comprise" a component or step are open, and they include or read on those compositions or methods plus an additional component(s) or step(s). Similarly, disclosed compositions, devices, articles of manufacture or methods that "consist of" a component or step are closed, and they would not include or read on those compositions or methods having appreciable amounts of an additional component(s) or an additional step(s). Furthermore, use of the term "including" as well as other forms, such as "include", "includes," and "included," is not limiting. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. Unless otherwise indicated, conventional methods of massPATENT Docket No. EPN-AC-500PC

[0065] spectroscopy, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology are employed.

[0066]

[0037] " Bond" or "single bond" as used herein means a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure. As explicitly stated, or implied by context, when a group described herein is a bond, the referenced group is absent thereby allowing a bond to be formed between the remaining identified groups.

[0067]

[0038] " Membered ring" as used herein means any cyclic structure. The term "membered" is meant to denote the number of skeletal atoms that constitute the ring. Thus, by way of example and not limitation, those membered rings include cyclohexyl, pyridinyl, pyranyl and thiopyranyl, which are exemplary 6-membered rings and cyclopentyl, pyrrolyl, furanyl, and thienyl, which are exemplary 5-membered rings.

[0068]

[0039] " Moiety" as used herein means a specific segment, fragment or functional group of a molecule or compound. Chemical moieties are sometimes indicated as chemical entities that are embedded in or appended (i.e., a substituent or variable group) to a larger molecule or compound.

[0069]

[0040] “Alkyl” as used herein means methyl or a collection of carbon atoms that are covalently linked together in normal, secondary, tertiary or cyclic arrangements, i.e., in a linear, branched, cyclic arrangement or some combination thereof. An alkyl substituent to a structure is that chain of carbon atoms that is covalently attached to the structure through a sp3carbon of the substituent. The alkyl substituents, as used herein, is fully saturated or contains one or more saturated moieties or groups and additionally contain unsaturated alkyl moieties or groups, i.e., the substituent comprises one, two, three or more independently selected double bonds or triple bonds of a combination thereof, typically one double or one triple bond if such unsaturated alkyl moieties or groups are present. When an alkyl moiety is used as a Markush group (i.e., a substituent) the alkyl moiety is attached to a Markush formula with which it is associated through a sp3carbon atom of the alkyl moiety, which is typically fully saturated (i.e., saturated alkyl as further defined herein).

[0070]

[0041] Unsaturated alkyl moieties or groups include moieties or groups as described below for alkenyl, alkynyl, cycloalkyl, and aryl moieties. Saturated alkyl moieties contain saturated carbon atoms (sp3) and no aromatic, sp2or sp carbon atoms. The number of carbon atoms in an alkyl moiety or group vary and typically is 1 to about 50, e.g., about 1-30 or about 1-20, unless otherwise specified, e.g., Ci-8alkyl or C1-C8 alkyl means an alkyl moiety containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms and Ci-6alkyl or C1 -C6 means an alkyl moiety containing 1, 2, 3, 4, 5 or 6 carbon atoms.

[0071] PATENT Docket No. EPN-AC-500PC

[0072]

[0042] When an alkyl substituent, moiety or group is specified, species include without limitation methyl, ethyl, 1 -propyl (n-propyl), 2-propyl ( / so-propyl, -CH(CH3)2), 1 -butyl (n-butyl), 2-methyl-1 -propyl ( / so-butyl, -CH2CH(CH3)2), 2-butyl (sec-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (t-butyl, -C(CH3)3), amyl, isoamyl, sec-amyl and other linear, cyclic and branch chain alkyl moieties. Unless otherwise specified or implied by context, alkyl groups in some aspects contain species and groups described below for cycloalkyl, alkenyl, alkynyl groups, aryl groups, arylalkyl groups, alkylaryl groups.

[0073]

[0043] Cycloalkyl as used here is a monocyclic, bicyclic or tricyclic ring system composed of only carbon atoms. The term "cycloalkyl" encompasses a monocyclic or polycyclic aliphatic, non-aromatic radical, wherein each of the atoms forming the ring (i.e., skeletal atoms) is a carbon atom. The number of carbon atoms in a cycloalkyl substituent, moiety or group vary and typically is 3 to about 50, e.g., about 1 -30 or about 1-20, unless otherwise specified, e.g, C3.8alkyl or C3-C8 alkyl means a cycloalkyl substituent, moiety or group containing 3, 4, 5, 6, 7 or 8 carbon atoms and C3.salkyl or C3-C6 means a cycloalkyl substituent, moiety or group containing 3, 4, 5 or 6 carbon atoms. Cycloalkyl substituents, moieties or groups will typically have 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms and in some aspects contain exo or endo-cyclic double bonds or endo-cyclic triple bonds or a combination of both wherein the endo-cyclic double or triple bonds, or the combination of both, do not form a cyclic conjugated system of 4n + 2 electrons; wherein the bicyclic ring system in some aspects shares one (i.e., spiro ring system) or two carbon atoms and the tricyclic ring system may share a total of 2, 3 or 4 carbon atoms, typically 2 or 3.

[0074]

[0044] Unless otherwise specified, cycloalkyl substituents, moieties or groups in some aspects contain moieties and groups described for alkenyl, alkynyl, aryl, arylalkyl, alkylaryl and the like and in some aspects contain one or more other cycloalkyl moieties. Thus, cycloalkyls are saturated, or partially unsaturated. Cycloalkyls in some aspects are fused with an aromatic ring, and the points of attachment to the aromatic ring are at a carbon or carbon atoms of the cycloalkyl substituent, moiety or group that is not an aromatic ring carbon atom. Cycloalkyl groups include groups having from 3 to 10 ring carbon atoms. In particular, a cycloalkyl moiety or substituent is monocyclic, preferably one that is 5- or 6-membered.

[0075]

[0045] Cycloalkyl substituents, moieties or groups include cyclopropyl, cyclopentyl, cyclohexyl, adamantly or other cyclic all carbon containing moieties. Cycloalkyls further include cyclobutyl, cyclopentenyl, cyclohexenyl, cycloheptyl and cyclooctyl. Cycloalkyl groups are substituted or unsubstituted. Depending on the substituent

[0076] PATENT Docket No. EPN-AC-500PC

[0077] structure, a cycloalkyl substituent is a monoradical or a diradical (i.e., a cycloalkylene, such as, but not limited to, cycloheptane-1,1-diyl, cyclobutan-1, 1 -diyl, cyclopentan-1,1 -diyl, cyclohexan-1,1-diyl, cyclohexan-1,4-diyl, cycloheptan-1, 1 -diyl, and the like). When cycloalkyl is used as a Markush group (i.e., a substituent) the cycloalkyl is attached to a Markush formula with which it is associated through a carbon atom involved in a cyclic carbon ring system of the cycloalkyl group that is not an aromatic carbon.

[0078]

[0046] " Alkylamine" as used herein means an -N(alkyl)xHygroup, moiety or substituent where subscripts x and y are independently selected from the group x=1, y=1 and x=2, y=0, wherein the subscripts define a monovalent group, moiety or substituent.

[0079] Alkylamine includes those -N(alkyl)xHygroups wherein x=2 and y=0 and the alkyl groups taken together with the nitrogen atom to which they are attached form a cyclic ring system, in particular a 5- or 6-membered heterocycle.

[0080]

[0047] " Heteroalkylene" as used herein means an alkylene (i.e., alkanediyl) group, moiety or substituent in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof, in particular selected from oxygen and nitrogen. Heteroalkylene includes Ci-C6heteroalkylene or C1-C4 heteroalkylene. Exemplary heteroalkylenes include, but are not limited to -OCH2-, -OCH(CH3)-, -OC(CH3)2-, -OCH2CH2-, -CH2O-, -CH(CH3)O-, C(CH3)2O-, -CH2CH2O-, -CH2OCH2-, -CH2OCH2CH2-, -CH2CH2OCH2-, -SCH2-, -SCH(CH3)-, -SC(CH3)2-, -SCH2CH2-, -CH2S-, -CH(CH3)S-, -C(CH3)2S-, -CH2CH2S-, -CH2SCH2-,-CH2SCH2CH2-, -CH2CH2SCH2-, -S(=O)2CH2-, -S(=O)2CH(CH3)-, -S(=O)2C(CH3)2-, -S(=O)2CH2CH2-, -CH2S(=O)2-, -CH(CH3)S(=O)2-, -C(CH3)2S(=O)2-, -CH2CH2S(=O)2-, -CH2S(=O)2CH2-,

[0081] -CH2S(=O)2CH2CH2-, CH2CH2S(=O)2CH2-, -NHCH2-, -NHCH(CH3)-, -NHC(CH3)2-, -NHCH2CH2-, -CH2NH-, -CH(CH3)NH-, -C(CH3)2NH-, -CH2CH2NH-, -CH2NHCH2-, -CH2NHCH2CH2-, and -CH2CH2NHCH2-.

[0082]

[0048] " Carboxylic acid bioisostere" as used herein means a functional group, moiety or substituent that exhibits one of more similar physical, biological and / or chemical properties as a carboxylic acid moiety. By way of example and not limitation, carboxylic acid bioisosteres include,

[0083]

[0084] PATENT Docket No. EPN-AC-500PC

[0085]

[0049] “Alkenyl” as used herein means a substituent, moiety or group that comprises one or more double bond moieties (e.g., =CH2, or -CH=CH-) or 1, 2, 3, 4, 5 or 6 or more, typically 1, 2 or 3 such moieties and in some aspects additionally comprises linked normal, secondary, tertiary and / or cyclic sp3carbon atoms, i.e., linear, branched, cyclic or any combination thereof unless the alkenyl moiety is a methylene or vinyl moiety (e.g., =CH2or -CH=CH2). An alkenyl moiety, group or substituent with multiple double bonds have the double bonds arranged contiguously (i.e., a 1,3 butadienyl moiety) or non-contiguously with one or more intervening saturated carbon atoms or a combination thereof, provided that a cyclic, contiguous arrangement of double bonds do not form a cyclically conjugated system of 4n + 2 electrons (i.e., is not aromatic). The number of carbon atoms in an alkenyl group or moiety vary and typically is 2 to about 50, e.g., about 2-30 or about 2-20, unless otherwise specified, e.g., C2-8 alkenyl or C2-8 alkenyl means an alkenyl moiety containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms and C2.s alkenyl or C2-6 alkenyl means an alkenyl moiety containing 2, 3, 4, 5 or 6 carbon atoms. Alkenyl moieties or groups will typically have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms, in particular 2 to 8 or 2 to 6 carbon atoms.

[0086]

[0050] When an alkenyl moiety, group or substituent is specified, species include, by way of example and not limitation, any of the alkyl or cycloalkyl, groups moieties or substituents described herein that has one or more double bonds, methylene (=CH2), methylmethylene (=CH-CH3), ethylmethylene (=CH-CH2-CH3), =CH-CH2-CH2-CH3, vinyl (-CH=CH2), allyl, 1-methylvinyl, butenyl, iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1 -hexenyl, 3-hexenyl, cyclohexenyl and other linear, cyclic and branched chained all carbon containing moieties containing at least one double bond. When alkenyl is used as a Markush group (i.e., a substituent) the alkenyl is attached to a Markush formula with which it is associated through an unsaturated (i.e., sp2carbon atom of a double bond of the alkenyl moiety or group unless specified otherwise or implied by context.

[0087]

[0051] “Alkynyl” as used herein means a substituent, moiety or group that comprises one or more triple bond moieties (i.e., -C=C-), e.g., 1, 2, 3, 4, 5, 6 or more, typically 1 or 2 triple bonds, optionally comprising 1, 2, 3, 4, 5, 6 or more double bonds, with the remaining bonds (if present) being single bonds and comprising linked normal, secondary, tertiary or cyclic carbon atoms, i.e., linear, branched, cyclic or any combination thereof, unless the alkynyl moiety is ethynyl. The number of carbon atoms in an alkenyl moiety or group vary and typically is 2 to about 50, e.g., about 2-30 or about 2-20, unless otherwise specified, e.g., C2.8alkynyl or C2-8 alkynyl meansPATENT Docket No. EPN-AC-500PC

[0088] an alkynyl moiety containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms. Alkynyl groups will typically have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms, in particular 2 to 8 or 2 to 6 carbon atoms.

[0089]

[0052] When an alkynyl moiety or group is specified, species include, by way of example and not limitation, any of the alkyl moieties, groups or substituents described herein that has one or more triple bonds, including without limitation ethynyl, propynyl, butynyl, iso-butynyl, 3-methyl-2-butynyl, 1 -pentynyl, cyclopentynyl, 1-methyl-cyclopentynyl, 1 -hexynyl, 3-hexynyl, cyclohexynyl and other linear, cyclic and branched chained all carbon containing moieties containing at least one triple bond. When an alkynyl is used as a Markush group (i.e., a substituent) the alkynyl is attached to a Markush formula with which it is associated through one of the unsaturated (i.e., sp) carbons of the alkynyl functional group.

[0090]

[0053] " Aromatic" as used herein refers to a planar ring having a delocalized pi-electron system containing 4n+2 pi electrons, where n is a positive integer. Aromatic rings are typically be formed from five, six, seven, eight, nine, ten, or more than ten atoms.

[0091] Aromatics are unsubstituted or substituted. The term "aromatic" includes both carbocyclic aryl ("aryl", e.g., phenyl) and heterocyclic aryl (or "heteroaryl" or "heteroaromatic") groups (e.g., pyridine). The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups.

[0092]

[0054] " Aryl” as used here means an aromatic ring system or a fused ring system with no ring heteroatoms comprising 1, 2, 3 or 4 to 6 rings, typically 1 to 3 rings, wherein the rings contain only carbon atoms; and refers to a cyclically conjugated system of 4n + 2 electrons (Huckel rule), typically 6, 10 or 14 electrons, some of which may additionally participate in exocyclic conjugation (cross-conjugated, e.g., quinone). Aryl substituents, moieties or groups are typically formed by six, eight, or 10, carbon atoms. Aryl substituents, moieties or groups are unsubstituted or substituted. Exemplary aryls include C6-C10 aryls such as phenyl and naphthalenyl and phenanthryl. Depending on the structure, an aryl group is a monoradical or a diradical (i.e., an arylene group). Exemplary arylenes include, but are not limited to, phenyl-1,2-ene, phenyl-1,3-ene, and phenyl-1,4-ene. When aryl is used as a Markush group (i.e., a substituent) the aryl is attached to a Markush formula with which it is associated through an aromatic carbon of the aryl group.

[0093]

[0055] “Arylalkyl” as used herein means a substituent, moiety or group where an aryl moiety is bonded to an alkyl moiety, i.e., -alkyl-aryl, where alkyl and aryl groups are as described above, e.g., -CH2-C6H5or -CH2CH(CH3)-C6H5. When arylalkyl is used as a Markush group (i.e., a substituent) the alkyl moiety of the arylalkyl is attached to aPATENT Docket No. EPN-AC-500PC

[0094] Markush formula with which it is associated through a sp3carbon atom of its alkyl moiety.

[0095]

[0056] “Alkylaryl” as used herein means a substituent, moiety or group where an alkyl moiety is bonded to an aryl moiety, i.e., -aryl-alkyl, where aryl and alkyl groups are as described above, e.g., -C6H4-CH3or -C6H4-CH2CH(CH3). When alkylaryl is used as a Markush group (i.e., a substituent) the aryl moiety of the alkylaryl is attached to a Markush formula with which it is associated through an aromatic sp2carbon atom of the aryl moiety.

[0096]

[0057] “Substituted alkyl”, “substituted cycloalkyl”, “substituted alkenyl”, “substituted alkynyl”, substituted alkylaryl”, “substituted arylalkyl”, “substituted heterocycle”, “substituted aryl” and the like as used herein mean an alkyl, alkenyl, alkynyl, alkylaryl, arylalkyl heterocycle, aryl or other group or moiety as defined or disclosed herein that has a substituent(s) that replaces a hydrogen atom(s) or a substituent(s) that interrupts a carbon atom chain. Alkenyl and alkynyl groups that comprise a substituent(s) are substituted at a carbon atom that is one or more methylene moieties removed from the double bond.

[0097]

[0058] “Optionally substituted alkyl”, “optionally substituted alkenyl”, “optionally substituted alkynyl”, “optionally substituted alkylaryl”, “optionally substituted arylalkyl”, “optionally substituted heterocycle”, “optionally substituted aryl”, “optionally substituted heteroaryl", “optionally substituted alkylheteroaryl”, “optionally substituted heteroarylalkyl” and the like as used herein mean an alkyl, alkenyl, alkynyl, alkylaryl, arylalkyl heterocycle, aryl, heteroaryl, alkylheteroaryl, heteroarylalkyl, or other substituent, moiety or group as defined or disclosed herein that is unsubstituted or has a substituent(s) that replaces a hydrogen atom(s) or a substituent(s) that interrupts a carbon atom chain. Such substituents are as described herein. For a phenyl moiety, the arrangement of any two substituents present on the aromatic ring can be ortho (o), meta (m), or para (p). An optionally substituted fluoroalkyl is an alkyl or cycloalkyl moiety, typically a linear alkyl, wherein one or more hydrogen atoms is replaced by fluorine and at least one other atom other than carbon and fluorine.

[0098]

[0059] An optionally substituted or substituted substituent, moiety or group includes without limitation those having one or more additional group(s) that replace its hydrogen atom(s) individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, alkylthio, arylthiol, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, cyano, halo, nitro, haloalkyl, fluoroalkyl, fluoroalkoxy, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. By way of example and not limitation an optional substituent(s) include withoutPATENT Docket No. EPN-AC-500PC

[0099] limitation halide, -CN, -NO2, or LsRs, wherein each Ls is independently selected from the group consisting of a bond, -O-, -C(=O)-, -C(=O)O-, -S-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -C(=O)NH-, S(=O)2NH-, -NHS(=O)2, -OC(=O)NH-, -NHC(=O)O-, and -(Ci-C6alkylene)-; and each Rs is selected from the group consisting of -H, alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl. The protecting groups that form the protective derivatives of the above substituents are typically found in sources such as in “Protecting Groups in Organic Synthesis”, 4thEd., Greene, T. W. and Wuts, P. G. M., Wiley (2006). Optional substituents include those selected from the group consisting of halogen, -CN, -NH2, -OH, -N(CH3)2, alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone, those selected from the group consisting of halogen, -CN, -NH2, -OH, NH(CH3), -N(CH3)2, -CO2H, -CO2alkyl,-C(=O)NH2, -C(=O)NHalkyl, -C(=O)N(alkyl)2, -S(=O)2NH2, -S(=O)2NH(alkyl),-S(=O)2N(alkyl)2, alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, -S-alkyl and-S(=O)2alkyl or those selected from the group consisting of halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, -CH3, -CH2CH3, -CF3, -OCH3, and -OCF3. Typically, an optionally substituted, substituent, moiety or group is substituted with one or two of the preceding groups, or more typically with one of the preceding groups. An optional substituent on an aliphatic carbon atom (acyclic or cyclic, saturated or unsaturated carbon atoms, excluding aromatic carbon atoms) further includes oxo (=0).

[0100]

[0060] “Heterocycle” or “heterocyclic” as used herein means a cycloalkyl or aromatic ring system wherein one or more, typically 1, 2 or 3, but not all of the carbon atoms contained within the ring system are replaced by a heteroatom, which is an atom other than carbon, including, N, O, S, Se, B, Si, P, typically N, O or S, wherein two or more heteroatoms are adjacent to each other or separated by one or more carbon atoms, typically 1-17 carbon atoms, 1-7 carbon atoms or 1-3 carbon atoms.

[0101] Heterocycles includes heteroaromatic rings (also known as heteroaryls) and heterocycloalkyl rings (also known as heteroalicyclic groups) containing one to four heteroatoms in the ring(s), where each heteroatom in the ring(s) is selected from the group consisting of O, S and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system, and with the proviso that the any ring does not contain two adjacent O or S atoms unless otherwise specified or implied by context.

[0102]

[0061] Non-aromatic heterocyclic, substituents, moieties or groups (also known as heterocycloalkyls) have at least 3 atoms in their ring system, and aromatic heterocyclic groups have at least 5 atoms in their ring system and include without limitation benzo-fused ring systems. Heterocyclics with 3, 4, 5, 6 and 10 atoms include without limitation aziridinyl azetidinyl, thiazolyl, pyridyl and quinolinyl,

[0103] PATENT Docket No. EPN-AC-500PC

[0104] respectively. Nonaromatic heterocyclic substituents, moieties or groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thieanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0)hexanyl, 3-azabicyclo[4.1.0)heptanyl, 3H-indolyl and quinolizinyl. Aromatic heterocyclic includes, by way of example and not limitation, pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzo-thiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Non-aromatic heterocycles further included those substituted with one or two oxo (=0) moieties, and includes pyrrolidin-2-one.

[0105]

[0062] When heterocycle is used as a Markush group (i.e., a substituent) the heterocycle is attached to a Markush formula with which it is associated through a carbon atom or a heteroatom of the heterocycle, where such an attachment does not result in an unstable or disallowed formal oxidation state of that carbon atom or heteroatom. A heterocycle that is C-linked is bonded to a molecule or a Markush formula through one of its carbon atoms and is sometimes described as -C<heterocycle where C< represents a carbon atom in a heterocycle ring. A heterocycle that is N-linked is a nitrogen containing heterocycle that is bonded to a molecule or a Markush formula through a heterocycle ring nitrogen atom and is sometimes described as -N<heterocycle where N< represents a nitrogen atom in a heterocycle ring. Thus, nitrogen-containing heterocycles may be C-linked or N-linked and include pyrrole substituents, indicated as pyrrol-1-yl (N-linked) or pyrrol-3-yl (C-linked), imidazole substituents, indicated as imidazol-1-yl or imidazol-3-yl (both N-linked) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C-linked).

[0106]

[0063] “Heteroaryl” as used herein means an aryl ring system wherein one or more, typically 1, 2 or 3, but not all of the carbon atoms comprising the aryl ring system are replaced by a heteroatom which is an atom other than carbon, including, N, O, S, Se, B, Si, P, typically, oxygen (-0-), nitrogen (-NX-) or sulfur (-S-) where X is -H, a protecting group or Ci-6unsubstituted or substituted alkyl, wherein the heteroatomPATENT Docket No. EPN-AC-500PC

[0107] participates in the conjugated ring system either through pi-bonding with an adjacent atom in the ring system or through a lone pair of electrons on the heteroatom and is unsubstituted or substituted on one or more carbon atoms or heteroatoms, or a combination of both, in a manner which retains the cyclically conjugated system.

[0108]

[0064] Heterocycles and heteroaryls, include, by way of example and not limitation, heterocycles and heteroaryls described in Paquette, Leo A.; “Principles of Modern Heterocyclic Chemistry” (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; “The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. 1960, 82:5545-5473 particularly pages 5566-5573). Examples of heteroaryls include by way of example and not limitation pyridyl, thiazolyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, purinyl, imidazolyl, benzofuranyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, benzimidazolyl, pyridazinyl, pyrazinyl, benzothiopyran, benzotriazine, isoxazolyl, pyrazolopyrimidinyl, quinoxalinyl, thiadiazolyl, triazolyl and the like. Heterocycles that are not heteroaryls include, by way of example and not limitation, tetrahydrothiophenyl, tetrahydrofuranyl, indolenyl, piperidinyl, pyrrolidinyl, 2-pyrrolidonyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, 2H-pyrrolyl, 3H-indolyl, 4H-quinolizinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, piperazinyl, quinuclidinyl, morpholinyl, and oxazolidinyl.

[0109]

[0065] Other heteroaryls include, by way of example and not limitation, the following moieties:

[0110]

[0111]

[0066] Monocyclic heteroaryls include, by way of example and not limitation, pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, and furazanyl. Heteroaryls include those substituents, moieties or groupsPATENT Docket No. EPN-AC-500PC

[0112] containing 0-3 N atoms, 1-3 N atoms or 0-3 N atoms, 0-1 O atoms and 0-1 S atoms, wherein at least one such atom is present. A heteroaryl is typically monocyclic or bicyclic. The ring system of a heteroaryl ring typically contains 1-9 carbon atoms. Monocyclic heteroaryls include C5-C12 heteroaryls, wherein the subscript indicates the total number of atoms in the heteroaryl aromatic ring system inclusive of the heteroatom(s). Monocyclic heteroaryls include those having 5-membered or 6-membered ring systems. Bicyclic heteroaryls include C8-C12 heteroaryls. Depending on the structure, a heteroaryl group is a monoradical or a diradical (i.e., a heteroarylene group).

[0113]

[0067] " Heterocycloalkyl" or “heteroalicyclic” as used herein means a cycloalkyl group, moiety or substituent wherein at least one carbon atom of the cycloalkyl chain is replaced with a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur. The heterocycloalkyl is some aspects is fused with an aryl or heteroaryl.

[0114] Heterocycloalkyls, also referred to as non-aromatic heterocycles, include by way of example and not limitation:

[0115]

[0116]

[0068] Heterocycloalkyl includes, by way of example and not limitation, oxazolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, and indolinyl. Heteroalicyclics further includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides and oligosaccharides. Typically, a heterocycloalkyl is a C3-C12 heterocycloalkyl and includes C5-C12 heterocycloalkyl wherein the subscript indicates the total number of skeletal atoms of the heterocycloalkyl ring system inclusive of the heteoatom(s). Typically, a heterocycloalkyl contains 0-2 N atoms, 0-2 O atoms or 0-1 S atoms provided at least one such atom is present in the heterocycloalkyl ring system.

[0117]

[0069] “Heteroarylalkyl” as used herein means a substituent, moiety or group where a heteroaryl moiety is bonded to an alkyl moiety, i.e., -alkyl-heteroaryl, where alkyl and heteroaryl groups are as described above. When heteroarylalkyl is used as a Markush group (i.e., a substituent) the alkyl moiety of the heteroarylalkyl is attachedPATENT Docket No. EPN-AC-500PC

[0118] to a Markush formula with which it is associated through a sp3carbon atom of the alkyl moiety.

[0119]

[0070] “Alkylheteroaryl” as used herein means a substituent, moiety or group where a heteroaryl moiety is bonded to an alkyl moiety, i.e., -heteroaryl-alkyl, where heteroaryl and alkyl groups are as described above. When heteroarylalkyl is used as a Markush group (i.e., a substituent) the heteroaryl moiety of the heteroarylalkyl is attached to a Markush formula with which it is associated through a sp2carbon atom or heteroatom of the alkyl moiety.

[0120]

[0071] “Halogen” or “halo” as used herein means fluorine, chlorine, bromine or iodine, typically fluorine or chlorine.

[0121]

[0072] " Haloalkyl" as used herein means an alkyl substituent moiety or group in which one or more of its hydrogen atoms are replaced by one or more independently selected halide atoms. Haloalkyl includes Ci-C4haloalkyl. Exemplary but non-limiting Ci-C4haloalkyls are -CH2CI, CH2Br, -CH2I, -CHBrCI, -CHCI-CH2CI and -CHCI-CH2I and further include fluoroalkyl as defined herein unless indicated otherwise or implied by context.

[0122]

[0073] " Haloalkylene" as used herein means an alkylene substituent, moiety or group in which one or more hydrogen atoms are replaced by one or more halide atoms.

[0123] Haloalkylene includes Ci-C3haloalkylenes or Ci-C4haloalkylenes and further include fluoroalkylene as defined herein unless indicated otherwise or implied by context.

[0124]

[0074] " Fluoroalkyl" as used herein means an alkyl in which one or more hydrogen atoms are replaced by a fluorine atom. Fluoroalkyl includes Ci-C6and Ci-C4fluoroalkyls. Example but non-limiting fluoroalkyls include -CH3F, -CH2F2and -CF3and perfluroalkyls.

[0125]

[0075] " Fluoroalkylene" as used herein means an alkylene in which one or more hydrogen atoms are replaced by a fluorine atom. Fluoroalkylene includes Ci-C6fluoroalkylenes or Ci-C4fluoroalkylenes.

[0126]

[0076] The term "heteroalkyl" refers to an alkyl group in which one or more skeletal carbon atoms of an alkyl, typically one such atom, is replaced independently with a heteroatom, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof, in particular oxygen or nitrogen, provided that at least one carbon atom remains. In one aspect, a heteroalkyl is a C2-C3heteroalkyl wherein the subscript denotes the total number of contiguous atoms of the heteroalkyl inclusive of the heteroatom (s).

[0127]

[0077] “Protecting group” as used here means a moiety that prevents or reduces the ability of the atom or functional group to which it is linked from participating in unwanted reactions. Non-limiting examples are for -ORPR, wherein RPRis a

[0128] PATENT Docket No. EPN-AC-500PC

[0129] protecting group for the oxygen atom found in a hydroxyl functional group, while for -C(O)-ORPR, RPRis a carboxylic acid protecting group; for -SRPR, RPRis a protecting group for sulfur in a thiol functional group and for -NHRPRor -N(RPR)2-, at least one of RPRis a nitrogen atom protecting group for a primary or secondary amine. Hydroxyl, amine, ketones and other reactive groups is some aspects will require protection against reactions taking place elsewhere in the molecule. The protecting groups for oxygen, sulfur or nitrogen atoms are usually used to prevent unwanted reactions with electrophilic compounds, such as acylating agents. Typical protecting groups for atoms or functional groups are given in Greene (1999), “Protective groups in organic synthesis, 3rded.”, Wiley Interscience.

[0130]

[0078] “Ester” as used herein means a substituent, moiety or group that contains a -C(O)-O- structure (i.e., ester functional group) wherein the carbon atom of the structure is not directly connected to another heteroatom and is directly connected to -H or another carbon atom. Typically, esters comprise or consist of an organic moiety other than the ester functional group containing 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e g., O, S, N, P, Si), typically 0-2, in particular selected from O, S and N, wherein the organic moiety is bonded through the -C(O)-O- structure and includes ester moieties such as organic moiety-C(O)-O-. The organic moiety usually comprises one or more of any of the organic groups described herein, e.g., C1-20 alkyl moieties, C2-20 alkenyl moieties, C2-20 alkynyl moieties, aryl moieties, C3-C8heterocycles or substituted derivatives of any of these, e.g., comprising 1, 2, 3, 4 or more substituents, in particular 1 or 2 substituents, wherein each substituent is independently chosen. Exemplary, nonlimiting substitutions for hydrogen or carbon atoms in these organic groups are as described above for substituted alkyl and other substituted moieties and are independently chosen. The substitutions listed above are typically substituents that are sometimes used to replace one or more carbon atoms, e.g., -O- or -C(O)-, or one or more hydrogen atoms, e.g., halogen, -NH2or -OH. Exemplary esters include by way of example and not limitation, acetate, propionate, isopropionate, isobutyrate, butyrate, valerate, isovalerate, caproate, isocaproate, hexanoate, heptanoate, octanoate, phenylacetate esters and benzoate esters. When ester is used as a Markush group (i.e., a substituent) the single bonded oxygen of the ester functional group is attached to a Markush formula with which it is associated. When the organic moiety of an ester is an alkyl group as defined herein such esters are typically C1-C8or C2-C6esters in which the subscript denotes the total number of carbon atoms of the ester substituent inclusive of the carbon atom of the ester functional group. Thus, a Ci ester is formate (-OC(=O)H) and a C2 ester is acetate (-OC(=O)CH3).

[0131] PATENT Docket No. EPN-AC-500PC

[0132]

[0079] “Acetal”, “thioacetal”, "ketal", "thioketal" and the like as used herein means a moiety, group or substituent comprising or consisting of a carbon atom to which is bonded two of the same or different heteroatoms wherein the heteroatoms are independently selected S and O. For acetal the carbon atom has two bonded oxygen atoms each of which is covalently bonded to an independently selected unsubstituted or substituted alkyl moiety or are interconnected with an unsubstituted or substituted alkylene moiety, a hydrogen atom and an organic moiety. For ketal, the carbon atom has two bonded oxygen atoms each of which is covalently bonded to an independently selected unsubstituted or substituted alkyl moiety or are interconnected with an unsubstituted or substituted alkylene moiety and two independently selected organic moieties where the organic moiety in some aspects is an unsubstituted or substituted alkyl as described herein. For thioacetals and thioketals one or both of the oxygen atoms in acetal or ketal, respectively, is replaced by sulfur. As previously indicated, the oxygen or sulfur atoms in ketals and thioketals are sometimes linked by an unsubstituted or substituted alkylene moiety. Typically, the alkylene moiety is an unsubstituted or substituted unbranched C1-C8alkylene or an unsubstituted or substituted branched C2-C8alkylene such as -C(CH3)2-, -CH(CH3)-, -CH2-, -CH2-CH2-, -C[(C2-C4alkyl)2]1,2,3- or -[CH(C2-C4alkyl)]1,2,3-. In some aspects the heteroatoms of an acetal or ketal serve as protecting groups for an aldehyde or ketone and include, by way of example and not limitation, acetals for aldehydes and ketals for ketones and contain -O-CH2-CH2-CH2-O- or -O-CH2-CH2-O-moieties that form a cyclic ring with the carbonyl carbon of the aldehyde or ketone to be protected, and is removable by chemical synthesis methods or by metabolism in cells or biological fluids.

[0133]

[0080] “Ether” as used herein means an organic moiety, group or substituent that comprises or consists of 1, 2, 3, 4 or more -O- moieties, usually 1 or 2, wherein no two -O- moieties are immediately adjacent (i.e., directly attached) to each other. Typically, ethers comprise an organic moiety containing 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., O, S, N, P, Si), typically 0-2. An ether moiety, group or substituent includes organic moiety-O- wherein the organic moiety is as described herein for alkyl, unsubstituted or substituted. When ether is used as a Markush group (i.e., a substituent) the oxygen of the ether functional group is attached to a Markush formula with which it is associated. When ether is a used as substituent in a Markush group it is sometimes designated as an "alkoxy" group. Alkoxy includes C1-C4ether substituents such as, by way of example and not limitation, methoxy, ethoxy, propoxy, iso-propoxy and butoxy. Ether further includesPATENT Docket No. EPN-AC-500PC

[0134] those substituents, moieties or groups that contain one (excluding ketal) or more -OCH2CH2O-, moieties in sequence (i.e., polyethylene or PEG moieties).

[0135]

[0081] “Carbonate” as used here means a substituent, moiety or group that contains a -O-C(=O)-O- structure (i.e., carbonate functional group). Typically, carbonate groups as used here comprise or consist of an organic moiety containing 1 -50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., O, S, N, P, Si), typically 0-2, preferably selected from O, S and N when present, bonded through the -O-C(=O)-O- structure, e.g., organic moiety-O-C(=O)-O-. When carbonate is used as a Markush group (i.e., a substituent) one of the singly bonded oxygen atoms of the carbonate functional group is attached to a Markush formula with which it is associated. When the organic moiety of a carbonate substituent, moiety or group is an alkyl group as defined herein such carbonate are typically C2-C6 carbonate in which the subscript denotes the total number of carbon atoms of the carbonate substituent inclusive of the carbon atom of the carbonate functional group.

[0136]

[0082] “Carbamate” or “urethane” as used here means a substituent, moiety or group that contains a -O-C(=O)N(RPR)-, -O-C(=O)N(RPR)2, -O-C(=O)NH(optionally substituted alkyl) or -O-C(=O)N(optionally substituted alkyl)2structure (i.e., carbamate functional group) where RPRand optionally substituted alkyl are independently selected and RPRare independently -H, a protecting group or an organic moiety as described for ester, alkyl or optionally substituted alkyl. Typically, carbamate groups as used herein comprise or consist of an organic moiety containing about 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., O, S, N, P, Si), typically 0-2, preferably selected from O, S and N when present, bonded through the -O-C(=O)-NRPR- structure, e.g., organic moiety-O-C(=O)-NRPR- or -O-C(=O)-NRPR-organic moiety. When carbamate is used as a Markush group (i.e., a substituent) the singly bonded oxygen (O-linked) or nitrogen (N-linked) of the carbamate functional group is attached to a Markush formula with which it is associated. The linkage of the carbamate substituent is either explicitly stated (N- or O-linked) or implicit in the context to which this substituent is referred. When the organic moiety of carbamate substituent is an alkyl group as defined herein such carbamates are typically C1-C8or C2-C6carbamates in which the subscript denotes the total number of carbon atoms of the carbamate substituent inclusive of the carbon atom of the carbamate functional group.

[0137]

[0083] For any substituent group or moiety described by a given range of carbon atoms, the designated range means that any individual number of carbon atoms is described,PATENT Docket No. EPN-AC-500PC

[0138] unless defined otherwise. Thus, reference to, e.g., “01-04 optionally substituted alkyl”, “02-6 optionally substituted alkenyl”, or 01-04 optionally substituted ether “specifically means that a 1, 2, 3 or 4 carbon optionally substituted alkyl moiety or ether functional group as defined herein is present, or a 2, 3, 4, 5 or 6 carbon alkenyl, or a 3, 4, 5, 6, 7 or 8 carbon moiety comprising an optionally substituted alkenyl moiety as defined herein is present. All such designations are expressly intended to disclose all of the individual carbon atom groups and thus “01-04 optionally substituted alkyl” includes, e.g., methyl and ethyl, optionally substituted, 3 carbon alkyl, 3 carbon substituted alkyl, 4 carbon alkyl and 4 carbon substituted alkyl, including all positional isomers are disclosed and are sometimes expressly referred to or named. As previously indicated for esters, carbonates and carbamates defined by a given range of carbon atoms, the designated range includes the carbonyl carbon atom of the respective functional group. The organic substituents, moieties and groups described herein, and for other any other moieties described herein, usually will exclude unstable moieties except where such unstable moieties are transient species that one can use to make a compound with sufficient chemical stability for the one or more of the uses described herein.

[0139] Substituents, moieties or groups by operation of the definitions herein that results in those having a pentavalent carbon are specifically excluded.

[0140]

[0084] “LPA-dependent”, “LPA-mediated” or like terms as used herein means a disease or condition whose etiology, progression or persistence is affected by in whole or in part by signaling through one or more lysophosphatidic acid receptor subtypes, including by way of example and not limitation lysophosphatidic acid receptor subtypes 1-6 (LPARs). LPA-dependent or LPA-mediated diseases and conditions include but are not limited to diseases of the bile duct and liver (e.g., cholangiopathies including primary biliary cholangitis, primary sclerosing cholangitis and biliary atresia).

[0141]

[0085] “LPAR1 selective agents” and LPAR1 selective compounds” as used herein means agents or compounds that interact with the lysophosphatidic acid subtype 1 receptor in preference to the lysophosphatidic acid receptor 2-6. Typically, that preference is manifested by 2-10-fold stronger binding affinity of the agent to LPAR1 in comparison to other known LPARs as measured by experimentally determined KDvalues in a suitable in vitro test system.

[0142]

[0086] " Pharmaceutically acceptable formulation" as used herein means a composition comprising an active pharmaceutical ingredient, such as a compound named or defined herein in addition to one or more pharmaceutically acceptable excipients or refers to a composition prepared from an active pharmaceutical ingredient and one or more pharmaceutically acceptable excipients, wherein the composition is suitable for

[0143] PATENT Docket No. EPN-AC-500PC

[0144] administration to a subject, such as a human or an animal, in need thereof. For a pharmaceutically acceptable formulation to be suitable for administration to a human the formulation must have biological activity for treating or preventing a disease or condition disclosed herein or an expectation must exist that the formulation would have a desired activity towards an “intent to treat” disease or condition. Typically, the “intent to treat” disease or condition is a liver fibrosis-related condition or disease. A pharmaceutically acceptable formulation that is suitable for administration to an animal does not necessarily require a biological activity for treating or preventing a disease or condition, and is usually administered to the animal in order to evaluate a potential pharmacological or biological activity of the compounds named. Those formulations must therefore be suitable for treating or preventing a disease or condition disclosed herein in an animal in need thereof or is suitable for evaluating a pharmacological or biological activity the compounds named herein. Compositions that are suitable only for use with in vitro assays or which contain a vehicle, component or excipient in an amount not permitted in a drug product are specifically excluded from the definition of a pharmaceutically acceptable formulation.

[0145]

[0087] The pharmaceutically acceptable formulations are comprised of, or be prepared from, one, two or more of the compounds named or defined herein, typically one or two, and one or more pharmaceutically acceptable excipients. In some aspects the formulations will consist essentially of or consist of two compounds and one or more pharmaceutically acceptable excipients. In other aspects a pharmaceutically acceptable formulation is comprised of, consist essentially of, or consist of a LPAR1 selective inhibitor compound named or defined herein and / or an incretin hormone receptor agonist and one or more pharmaceutically acceptable excipients.

[0146]

[0088] " Solid formulation" as used herein refers to a pharmaceutically acceptable formulation comprising at least one compound named or defined herein in solid form of the present invention and one or more pharmaceutically acceptable excipients wherein the formulation is in a unit dosage form suitable for administration of a solid or a suspension of the compound(s) of the present invention. The dosage units include tablets, capsules, caplets, gelcaps, suspensions and other dosage units typically associated with enteral (oral) administration of a solid or a suspension typically associated with parenteral administration. In some aspects a solid formulation is comprised, consisting essentially or consists of a LPAR1 selective inhibitor compound and / or an incretin hormone receptor agonist and one or more pharmaceutically acceptable excipients appropriate for a solid formulation.

[0147] PATENT Docket No. EPN-AC-500PC

[0148]

[0089] " Liquid formulation" as used herein refers to a pharmaceutically acceptable formulation wherein at least one compound of the present invention has been admixed or contacted with one or more pharmaceutically acceptable excipients, wherein at least one of the excipients is in liquid form in proportions required for a liquid formulation, i.e., such that a majority of the mass amount of the invention compound(s) and the nonliquid excipients are dissolved into the excipient in liquid form. Dosage units containing a liquid formulation include syrups, gels, ointments and other dosage units typically associated with parenteral or enteral administration of a pharmaceutical formulation to a subject in need thereof in liquid form.

[0149]

[0090] “Fixed Dose Combination” as used herein refers to a pharmaceutically acceptable formulation wherein two or more of the compounds named or defined herein at their pharmacologically active doses are combined with one or more pharmaceutically acceptable excipients to provide a unit dose in either a solid or liquid formulation. In some aspects a fixed dosage formulation is comprised, consisting essentially or consists of an effective amount of a LPAR1 selective inhibitor compound and an effective amount of an incretin hormone receptor agonist and one or more pharmaceutically acceptable excipients appropriate for a unit dosage form for treating a liver fibrosis disease or condition as defined herein.

[0150]

[0091] “Prevent, “preventing” and like terms as used herein takes on its normal and customary meaning in the medical arts and therefore does not require that each instance to which the term refers be avoided with certainty.

[0151]

[0092] “Cytokines” as used herein refers to any one of the cell-signaling protein molecules that are secreted by cells of the immune system that have immunomodulating activity. Of particular interest is transforming growth factor (TGF), tumor necrosis factor (TNF) and interleukins.

[0152]

[0093] The terms “biomarker”, “biomarkers”, “marker” or “markers” as used herein refer to without limitation, cytokines, chemokines, growth factors, proteins, peptides, nucleic acids, oligonucleotides, and metabolites, together with their related metabolites, mutations, variants, polymorphisms, modifications, fragments, subunits, degradation products, elements, and other analytes or sample defined measures that may be used to convey, infer or determine a pharmacological outcome. Markers can also include mutated proteins, mutated nucleic acids, variations in copy numbers and / or numbers in transcript variants. Markers also encompass non-blood borne and non-analyte physiological markers of health status, and / or other factors not measured from samples (e.g. Biological samples such as body fluids), such as clinical parameters and traditional parameters for clinical assessment. Markers can also include any indices that are

[0153] PATENT Docket No. EPN-AC-500PC

[0154] calculated and / or created mathematically. Markers can also include combinations of the foregoing measurements, including temporal trends and differences. In some aspects biomarkers include PDGFp, MIP1a, TNFa, MCP-1, IL-2, IL-6, IL-8, FGFp, IL-7, TGF, IL-13, IL-17, IL-5, MIP1, CTGF, aSMA, FSP-1, Col-3a, Col-IVa, and fibrosis score.

[0155]

[0094] Numbered embodiments

[0156]

[0095] The following embodiments exemplify the invention and are not meant to limit the invention in any manner.

[0157]

[0096] Embodiment 1. A method of use of a lysophosphatidic acid receptor subtype 1 selective (LPAR1) antagonist for the treatment of a cholangiopathy

[0158]

[0097] Embodiment 2. The method of Embodiment 1 wherein the cholangiopathy is selected from the list of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and biliary atresia (BA).

[0159]

[0098] Embodiment 3. The method of Embodiment 2 wherein the cholangiopathy is primary biliary cholangitis (PBC).

[0160]

[0099] Embodiment 4. The method of any one of Embodiments 1-3, wherein the LPAR1 antagonist has the structure of:

[0161]

[0162]

[0101] or a salt, in particular, a pharmaceutically acceptable salt, or prodrug thereof, O)NH2, -C(=O)NHRB,

[0163]

[0164]

[0165]

[0104] RBis unsubstituted or substituted C1-C4 alkyl or has the structure of one of:

[0166]

[0167]

[0105] wherein RBis substituted or unsubstituted C1-C4 alkyl;

[0168] PATENT Docket No. EPN-AC-500PC

[0169]

[0106] L1is absent or is substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted Ci-Cs fluoroalkylene, substituted or unsubstituted C3-Cs cycloalkylene, substituted or unsubstituted Ci-C3heteroalkylene;

[0170]

[0107] wherein A1is -N= or -CH;

[0171]

[0108] wherein Ring A has the structure of:

[0172]

[0173]

[0109]

[0174]

[0110] wherein Rcis -CN, -F, -Cl, -Br, -I, -OC1-C4 alkyl, C3-C6cycloalkyl, or C1-C4 fluoroalkyl;

[0175]

[0111] and RDis -N(RF)-C(=O)XCH(RG)-CY, wherein X is O and CY is phenyl substituted with one RHso that RDhas the structure of:

[0176]

[0177]

[0112] RB, RFand RGindependently are -H or C1-C4 alkyl or C3-C6 cycloalkyl or REand RFindependently are -H or C1-C4 alkyl or Ci-C6cycloalkyl and one RGis -C1-C4 alkyl and is taken together with the RHphenyl moiety of the Ring A RDsubstituent and the carbon atom to which RGand said phenyl moiety is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle;

[0178]

[0113] RHis absent or is halogen, -CN, -NO2, -OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, or C1-C4 alkoxy.

[0179]

[0114] Embodiment 5, The method of Embodiment 4 wherein Rcis -CN, -F, -Cl, -Br, -I, -OC1-C4 alkyl, C1-C4 alkyl, C3-C6cycloalkyl, or C1-C4 fluoroalkyl and RDis -N(RF)-C(=O)OCH(RG)-CY, wherein RFand each RGindependently are -H or C1-C4 alkyl.

[0180]

[0115] Embodiment 6, The method of Embodiments 4 or 5, wherein RAis -CO2H, -CONHCN, tetrazolyl, or -C(=O)NHSO2RB, wherein RBis substituted or unsubstituted C,-C4alkyl.

[0181]

[0116] In particular, RAis -CO2H, -CONHCN, tetrazolyl, or -C(=O)NHSO2RB, wherein RBis -CH3.

[0182] PATENT Docket No. EPN-AC-500PC

[0183]

[0117] Embodiment 7. The method of any one of Embodiments 4-6, wherein L1is substituted or unsubstituted Ci-Ce alkylene, Ci-Ce fluoroalkylene, or substituted or unsubstituted Ci-C6heteroalkylene.

[0184]

[0118] In particular

[0185]

[0186]

[0119] Embodiment 8. The method of any one of Embodiments 4-7 wherein Rcis -CN, -F, -Cl, or C1-C4 fluoroalkyl.

[0187]

[0120] In particular, Rcis -F, or -Cl.

[0188]

[0121] Embodiment 9. The method of any one of Embodiments 4-8, wherein RDis -N(RF)C(=O)-OCH(RG)-CY, wherein RFis -H or C1-C4 alkyl.

[0189]

[0122] In particular, RDis -N(RF)C(=O)OCH(RG)-CY, wherein RFis -H.

[0190]

[0123] Embodiment 10. The method of Embodiment 9, wherein RFis -H, C1-C4 alkyl or C3-C6 cycloalkyl.

[0191]

[0124] Embodiment 11. The method of Embodiment 8 or 9, wherein RGis independently -H or C1-C4 alkyl.

[0192]

[0125] In particular RGis -CH3.

[0193]

[0126] Embodiment 12. The method of any one of Embodiments 11-18, wherein CY is phenyl substituted with 1 RH.

[0194]

[0127] Embodiment 13. The method of Embodiment 11, wherein RHis halogen, -CN, -NO2, -OH, substituted or unsubstituted Ci-C4alkyl, or substituted or unsubstituted C1-C4 alkoxy.

[0195]

[0128] Embodiment 14. The method of any one of Embodiments 4-13, wherein RHis halogen, unsubstituted C1-C4 alkyl or unsubstituted C1-C4 alkoxy.

[0196]

[0129] Embodiment 15. The method of any one of Embodiments 4-12, wherein CY is unsubstituted phenyl so that RHis absent.

[0197]

[0130] Embodiment 16. The method of any one of Embodiments 11-22, wherein RAis -CO2H, and Rcis -F or -Cl.

[0198]

[0131] Embodiment 17. The method of any one of Embodiments 4-15, wherein RAis tetrazolyl, and Rcis -F or -Cl.

[0199]

[0132] Embodiment 18. The method of any one of Embodiments 4-15, wherein RAis -C(=O)NHSO2RB, and Rcis -F or -Cl.

[0200]

[0133] Embodiment 19. The method of any one of Embodiments 4-15, wherein RAis -CONHCN, Rcis -F or -Cl.

[0201]

[0134] Embodiment 20. The method of any one of Embodiments 4-15, wherein RAis -CO2H or -CONHCN.

[0202] PATENT Docket No. EPN-AC-500PC

[0203]

[0135] Embodiment 21. The method of any one of Embodiments 4-15, wherein RAis tetrazolyl.

[0204]

[0136] Embodiment 22. The method of any one of Embodiments 1-18, wherein RAis -C(=O)NHSO2RBwherein RBis H or -CH3.

[0205]

[0137] Embodiment 23. The method of any one of Embodiments 4-15 wherein Rcis -CN, -F, or -Cl.

[0206]

[0138] Embodiment 24. The method of any one of Embodiments 4-15 and 20-23 wherein Rcis -F or -Cl.

[0207]

[0139] Embodiment 25. The method of any one of Embodiments 4-24 wherein L1is Ci-Csalkyl, wherein Ci-C6alkyl consists of a di-alkyl substituted methinyl carbon atom, a C3-Cscycloalk-1,1 -di-yl or a C3-Ceheterocycloalk-1,1 -di-yl moiety.

[0208]

[0140] Embodiment 26. The method of any one of Embodiments 4-26, wherein RGis -CH3. In particular, in an R-configuration

[0209]

[0141] Embodiment 27. The method of any one of Embodiment 1-26, wherein L1is

[0210]

[0142] Embodiment 28. The method of any one of Embodiments 1-3 wherein the selective LPAR1 antagonist is selected from the group consisting of (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-3-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1 - (4'-{5-[ 1 -(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1 -yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1 -(2-Chloro-4'-{5-[1-(2-chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1 - (4'-{5-[ 1 -(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-methyl-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)- 1-{4'-[5-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1 -yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, (R)-1 -{2-Fluoro-4'-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, (R)-1 - (4-{5-[5-(1 -Phenyl-ethoxycarbonylamino)-pyrazol-1 -yl]-pyridin-2-yl}-phenyl)-cyclopropanecarboxylic acid, (R)-1 -(4-(5-(5-(((1 -(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1 H-pyrazol-1 -yl)pyridin-2-yl)phenyl)cyclopropane-1 -carboxylic acid, (R)-1 -(4-(5-(4-chloro-5-(((1 -(2-chlorophenyl)ethoxy)carbonyl)amino)-1 H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1 -carboxylic acid, (R)-1 -(4'-(4-fluoro-5-(((1 -phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-[1,1'-biphenyl]-4-yl)cyclopropane-1 -carboxylic acid, (R)-1-(4'-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -y l)-[1,1 '-biphenyl]-4-yl)cyclopropane-1 -PATENT Docket No. EPN-AC-500PC

[0211] carboxylic acid, (R)-1-(3-fluoro-4'-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1 H-pyrazol-1-yl)-[1, T-biphenyl]-4-yl)cyclopropane-1 -carboxylic acid, (R)-1-(2-fluoro-4'-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1 H-pyrazol-1-yl)-[1,1'-biphenyl]-4-yl)cyclopropane-1 -carboxylic acid, (R)-1-(4'-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-3-fluoro-[1,1'-biphenyl]-4-yl)cyclopropane-1 -carboxylic acid, (R)-1-(4'-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-2-fluoro-[1,1'-biphenyl]-4-yl)cyclopropane-1 -carboxylic acid, (R)-1-(2-chloro-4'-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -y l)-[1,1 '-biphenyl]-4-yl)cyclopropane-1 -carboxylic acid, (R)-1-(2-chloro-4'-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-[1,1'-biphenyl]-4-yl)cyclopropane-1 -carboxylic acid, (R)-1-(4'-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-2-methyl-[1, 1’-biphenyl]-4-yl)cyclopropane-1 -carboxylic acid, (R)-1-(4'-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-2-methyl-[1,1 '-biphenyl]-4-yl)cyclopropane-1 -carboxylic acid, (R)-1-(2-chlorophenyl)ethyl (1-(4'-(1-carbamoylcyclopropyl)-[1, T-biphenyl]-4-yl)-4-fluoro-1 H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1 -(2’-f I uoro-4'-( 1 -((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate, (R)-1 -phenylethyl (4-fluoro-1-(2'-fluoro-4'-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate, (R)-1 -(2-chlorophenyl)ethyl (4-chloro-1 -(2'-f I uoro-4'-( 1 -((methylsulfonyl)carbamoyl)cyclopropyl)-[1, T-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate, (R)-1 -phenylethyl (4-chloro-1 - (4'-(1 -((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1 '-biphenyl] -4-yl)- 1 H-pyrazol-5-yl)carbamate, (R)-1 -(2-chlorophenyl)ethyl (4-fluoro-1 -(4'-(1 -((methylsulfonyl)carbamoyl)cyclopropyl)-[1, T-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate, (R)-1 -(2-chlorophenyl)ethyl (1 -(4'-(1 -(1 H-tetrazol-5-yl)cyclopropyl)-[1,1 ’-biphenyl] -4-yl) -4-fluoro-1 H-pyrazol-5-yl)carbamate, (R)-1 -phenylethyl (1-(4'-(1-(1 H-tetrazol-5-yl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-4-chloro-1 H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1 -(4'-(1 -(1 H-tetrazol-5-yl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-4-chloro-1 H-pyrazol-5-yl)carbamate, 3-[(R)-1 -Phenylethoxycarbonylamino]-4-chloro-2-{4'-[1 -(cyanoamino)carbonylcyclopropyl]-4-biphenylyl}-2H-pyrazole, 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-4-chloro-2-{4'-[1-(cyanoamino)carbonylcyclopropyl]-4-biphenylyl}-2H-pyrazole, 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-2-{4'-[1-(cyanoamino)carbonylcyclopropyl]-2'-fluoro-4-biphenylyl}-4-fluoro-2H-pyrazole, and salts thereof.

[0212]

[0143] Embodiment 29. The method of any one of Embodiments 1-3 wherein the LPAR1 antagonist is selected from the group consisting of BMS-986278 or (1S,3S)-3-((2-methyl-6-(1 -methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1 H-1,2, 3-triazol-4-PATENT Docket No. EPN-AC-500PC

[0213] yl)pyridin-3-yl)oxy)cyclohexane-1 -carboxylic acid, SAR-100842, which is 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1 H-indene-2-carboxylic acid, PIPE-791, which is trans-4-(3-(2-(difluoromethoxy)-6-methoxypyridin-3-yl)-1 -(2-isopropylphenyl)ureido)-cyclohexane-1 -carboxylic acid, ACT-1016-0707, which is N-(6-chloro-4-methoxypyridin-3-yl)-3-(2-isopropylphenyl)-1-sulfamoylazetidine-3-carboxamide, LTSE-2578, CTX-343 and salts thereof.

[0214]

[0144] Embodiment 30. The method of any one of Embodiments 1-3 wherein the LPAR1 antagonist is selected from the group described in publications US2017 / 360759, US9328071 B2, US20250034110A1, US20240400562A1, W02020254408A1, WO2021110805A1, US20170158663A1, WO2021020429A1, WO2015025164A1, US20150133512A1, US20150259295A1, WO2011037192A1, US20030114505A1, W02005058790A1, US2008 / 293764, US20130041000A1, US20130072490A1, US20130253004A1, US20130253023A1, WO2013025733A1, US8785442B2, WO2013189862A1, WO2012138648A1, WO2013 / 25733, WO2013 / 189865,

[0215] US2014 / 0329871 A1, US20220079928A1 and WO2011037192A1. US9321738, US9272990, US9090573, US8975235B2, US8785442, US8778983, US8664220, US8592402, US8440707, US8273780, US8217066, US8058300, US8048902, US7517996, US7288558, and US6964975, the structures of which are incorporated by reference herein.

[0216]

[0145] Embodiment 31. The method of any one of Embodiments 1 -3, wherein the LPAR1 antagonist is (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1 -yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid or a salt thereof.

[0217]

[0146] Embodiment 32. The method of any one of Embodiments 1-3, wherein the LPAR1 antagonist is (R)-1 -phenylethyl (4-chloro-1-(4'-(1-((methylsulfonyl)carbamoyl)-cyclopropyl)-[1,1'-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate or a salt thereof.

[0218]

[0147] Embodiment 33. The method of any one of Embodiments 1-31, wherein the method is for reducing portal inflammation with a LPAR1 antagonist from a cholangiopathy in a subject as measured by biopsy and subsequent analysis by Metavir scoring.

[0219]

[0148] Embodiment 34. The method of any one of Embodiments 1-31, wherein the method is for reducing fibrosis with a LPAR1 antagonist in a cholangiopathy in a subject measured by biopsy and analysis by Metavir scoring.

[0220]

[0149] Embodiment 35. The method of any one of Embodiments 1-31, wherein the method is for reducing bile duct injury with a LPAR1 antagonist in a cholangiopathy in a subject measured by biopsy.

[0221] PATENT Docket No. EPN-AC-500PC

[0222]

[0150] Embodiment 36. The method of any one of Embodiments 33-35 where the LPAR1 antagonist is selected from any one of Embodiments 4-32.

[0223]

[0151] Embodiment 37. The method of Embodiments 33-36 wherein the cholangiopathy is selected from the group consisting of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and biliary atresia (BA).

[0224]

[0152] Embodiment 38. The method of any one Embodiments 33-36 where the cholangiopathy is primary biliary cholangitis (PBC).

[0225]

[0153] Embodiment 39. A kit comprising a package containing one or more unit dosage forms of a pharmaceutically acceptable formulation comprised of an effective amount of a selective LPAR1 antagonist and a package insert or a label affixed to the package that indicates that each unit dosage form is to be administered to a subject with a cholangiopathy in combination with a pharmaceutically acceptable formulation of a compound according to any one of Embodiments 1 -32 for the treatment of a cholangiopathy.

[0226]

[0154] Embodiment 40. The kit of Embodiment 39 wherein the cholangiopathy is selected from the group consisting of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and biliary atresia (BA).

[0227]

[0155] Embodiment 41. The kit of Embodiment 39, wherein the cholangiopathy is primary biliary cholangitis (PBC).

[0228]

[0156] Embodiment 42. The kit of any one of Embodiments 39-41 wherein the subject is a human.

[0229]

[0157] Embodiment 43. A compound for use in treatment of a cholangiopathy in subject, wherein the compound is as defined in any one Embodiments 1-32.

[0230]

[0158] Embodiment 44. The compound of Embodiment 43, wherein the cholangiopathy is selected from the group consisting of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and biliary atresia (BA).

[0231]

[0159] Embodiment 45. The compound of Embodiment 43, wherein the cholangiopathy is primary biliary cholangitis (PBC).

[0232]

[0160] Embodiment 46. The compound of any one of Embodiments 43-15, wherein the subject is a human.

[0233]

[0161] Embodiment 47. Use of a compound in preparation of a medicant for the treatment of a cholangiopathy in subject, wherein the compound is as defined in any one Embodiment 1-32.

[0234]

[0162] Embodiment 48. The use according to Embodiment 47, wherein the cholangiopathy is selected from the group consisting of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and biliary atresia (BA).

[0235] PATENT Docket No. EPN-AC-500PC

[0236]

[0163] Embodiment 49. The use according to Embodiment 47, wherein the cholangiopathy is primary biliary cholangitis (PBC).

[0237]

[0164] Embodiment 50. The use according to any one of Embodiments 47-49, wherein the subject is a human.

[0238] EXAMPLES

[0239]

[0165] LPAR1 receptor antagonists described herein are prepared according to the following examples:

[0240]

[0166] HPLC Methods

[0241]

[0167] HPLC traces for examples synthesized were recorded using a HPLC consisting of Shimadzu HPLC pumps, degasser and UV detector, equipped with an Agilent 1100 series auto-sampler. A MS detector (APCI) PE Sciex API 150 EX was incorporated for purposes of recording mass spectral data. HPLC / mass traces were obtained using one of three chromatographic methods:

[0242]

[0168] Method i: Column Zorbax C18, size 4.6 mm X 7.5 cm; Solvent A: 0.05 % TFA in water, Solvent B: 0.05 % TFA in acetonitrile; Flow rate - 0.7 mL / min; Gradient: 5 % B to 100 % B in 9 min, hold at 100 % B for 4 min and 100 % B to 5 % B in 0.5 min; UV detector - channel 1 = 220 nm, channel 2 = 254 nm.

[0243]

[0169] Method 2: Column Zorbax C18, size 4.6 mm X 7.5 cm;

[0244] Solvent A: 0.05 % TFA in water, Solvent B: 0.05 % TFA in acetonitrile;

[0245] Flow rate - 0.7 mL / min; Gradient: 5 % B to 100 % B in 5 min, hold at 100 % B for 2 min and 100 % B to 5 % B in 0.5 min; UV detector - channel 1 = 220 nm, channel 2 = 254 nm.

[0246]

[0170] Method 3: Column SunFire™ (Waters) C18, size 2.1 mm X 50 mm;

[0247] Solvent A: 0.05 % TFA in water, Solvent B: 0.05 % TFA in acetonitrile;

[0248] Flow rate - 0.8 mL / min; Gradient: 10 % B to 90 % B in 2.4 min, hold at 90 % B for 1.25 min and 90 % B to 10 % B in 0.25 min, hold at 10 % B for 1.5 min.; UV detector -channel 1 = 220 nm, channel 2 = 254 nm.

[0249]

[0171] Example 1: (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid

[0250]

[0172] Step 1: Ethyl (E)-4-(dimethylamino)-2-oxo-but-3-enoate

[0251]

[0173] Ethyl pyruvate (5 g, 43.1 mmol) was dissolved in CH2Cl2(86 mL) and treated with dimethylformamide dimethylacetal (5.73 mL, 43.1 mmol). The reaction was stirred at room temperature for 2 hours and concentrated in vacuo. The crude was used as is in the next step. Yield = 7.4 g.

[0252]

[0174] Step 2: ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate

[0253] PATENT Docket No. EPN-AC-500PC

[0254]

[0175] 4-Bromophenyl hydrazine hydrochloride (2.0 g, 8.95 mmol) was dissolved in MeOH (18 mL) and treated with crude ethyl (E)-4-(dimethylamino)-2-oxo-but-3-enoate [Example 1, Step 1] (1.54 g, 9.0 mmol). The resulting mixture was stirred at room temperature for 6 hours. The volatiles were removed in vacuo and the residue was purified by chromatography on silica-gel, eluting with a 95:5 mixture of hexanes / ethyl acetate v / v, increasing the polarity to 9:1 over time. Two isomeric products were isolated: ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate as an orange solid (0.82 g, 2.78 mmol, 31 %) and ethyl 1-(4-bromophenyl)pyrazole-3-carboxylate as a red solid (0.44 g, 1.49 mmol, 17%).

[0255]

[0176] Ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate: HPLC (254 nm): Method 2 Rt 5.22 min. MS (ESI) m / z 297 [M + H+]; 294.8 [M + H+]; 252 [(M - EtO) + H+]; 250 [(M -EtO) + H+],1H NMR (500 MHz, CDCl3) δ7.69 (d, J = 1.9 Hz, 1 H); 7.58 (d, J= 8.7 Hz, 2 H); 7.32 (d, J= 8.7 Hz, 2 H); 7.03 (d, J= 1.9 Hz, 1 H); 4.26 (q, J= 7.1 Hz, 2 H); 1.28 (t, J= 7.1 Hz, 3 H).

[0256]

[0177] Ethyl 1-(4-bromophenyl)pyrazole-3-carboxylate:1H NMR (500 MHz, CDCl3) δ 7.91 (d, J= 2.4 Hz, 1 H); 7.65 (d, J= 7.2 Hz, 2 H); 7.60 (d, J= 7.2 Hz, 2 H); 7.00 (d, J = 2.4 Hz, 1 H); 4.44 (q, J= 7.0 Hz, 2 H); 1.43 (t, J= 7.0 Hz, 3 H).

[0257]

[0178] Step 3: 2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazole-3-carboxylic acid ethyl ester

[0258]

[0179] Ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate [Example 1, Step 2] (1.08 g, 3.68 mmol) was dissolved in acetonitrile (12 mL) and the resulting mixture was treated with glacial acetic acid (4.6 mL). To this solution, 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (Selectfluor®, 3.91 g, 11.04 mmol) was added in one portion and the resulting mixture was heated to 105 °C for 18 hours. The mixture was cooled to room temperature and the volatiles were removed in vacuo. The crude residue was loaded directly onto a silica-gel column and purified by elution with 95:5 mixture of hexanes / ethyl acetate v / v, increasing the polarity to 9:1 overtime. The product was isolated as a white solid (410 mg, 1.31 mmol, 36 %) and starting material was recovered (272 mg, 0.93 mmol, 25 %). For 2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazole-3-carboxylic acid ethyl ester: HPLC (254 nm): Method 3 Rt 2.97 min. MS (ESI) m / z 313.1 [M + H+],1H NMR (500 MHz, CDCl3) δ7.60 (s, 1 H); 7.58 (d, J= 9 Hz, 2 H); 7.29 (d, J= 9 Hz, 2 H); 4.30 (q, J= 7.1 Hz, 2 H); 1.28 (t, J= 7.1 Hz, 3 H).

[0259]

[0180] Step 4: 2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazole-3-carboxylic acid

[0260]

[0181] A stirred solution of 2-(4-bromo-phenyl)-4-fluoro-2H-pyrazole-3-carboxylic acid ethyl ester [Example 1, Step 3] (410 mg, 1.31 mmol) in THF (13 mL) was treated with LiOH 1 N aqueous solution (13 mL) and the resulting mixture was stirred at room temperature overnight. The reaction was deemed complete by thin layer

[0261] PATENT Docket No. EPN-AC-500PC

[0262] chromatography and HPLC / MS. The reaction mixture was partitioned between ethyl acetate and 1 N aqueous HCI solution (100 mL v / v) and transferred to a separatory funnel. The organic layer was separated and the aqueous layer was back-extracted with ethyl acetate (30 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the pure product as a white solid (347 mg, 1.22 mmol, 93 %). HPLC (254 nm): Method 3 Rt 2.82 min. MS (ESI) m / z 285.1 [M + H+],

[0263]

[0182] Step 5: (R)-[2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazol-3-yl]-carbamic acid 1-(2-chloro-phenyl)-ethyl ester

[0264]

[0183] 2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazole-3-carboxylic acid [Example 1, Step 4] (347 mg, 1.22 mmol) was suspended in toluene (12 mL) and treated with triethylamine (205 pL, 1.46 mmol). The resulting solution was treated with diphenylphosphoryl azide (316 pL, 1.46 mmol) and heated to 65 °C. (R)- 1-(2-Chloro-phenyl)-ethanol (230 mg,

[0265] 1.46 mmol) was added to the reaction mixture and the temperature was increased to 105 °C for 30 minutes, during which time vigorous gas evolution was observed. The reaction was brought to 65 °C and stirred at that temperature for 4 hours. The reaction was deemed complete by HPLC / MS. After cooling, the volatiles were removed in vacuo and the crude residue was purified by silica gel chromatography, eluting with a hexanes / ethyl acetate gradient. Product isolated as a white solid (452 mg, 1.03 mmol, 85 %). HPLC (254 nm): Method 3 Rt 3.16 min. MS (ESI) m / z 440.1 [M + H+],

[0266]

[0184] Step 6: (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1 -yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid

[0267]

[0185] A stirred suspension of (R)-[2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazol-3-yl]-carbamic acid 1-(2-chloro-phenyl)-ethyl ester [Example 1, Step 5] (88 mg, 0.2 mmol), 2:1 v / v toluene / ethanol (2 mL), 2 M aqueous solution of Na2CO3(670 pL) and 1-[4-(dihydroxyboranyl)-3-fluorophenyl]-cyclopropane-1 -carboxylic acid (45 mg, 0.2 mmol) was degassed under nitrogen for 10 minutes and treated with Pd[Ph3P]4(12 mg, 0.01 mmol). The resulting mixture was immersed in an oil bath with stirring at 90 °C for 12 hours. The reaction was cooled, transferred to a separatory funnel and diluted with ethyl acetate (50 mL). The mixture was carefully treated with 1 N aqueous HCI solution (20 mL). The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude residue was purified by preparative TLC plate (1000 pm), eluting with a 1:1 v / v hexanes / ethyl acetate mixture. The product was obtained as a tan solid. Yield 40 mg (37 %) as a light yellow solid. HPLC (254 nm): Method 3, Rt 3.14 min. MS (ESI) m / z 538.3 [M + H+],

[0268] PATENT Docket No. EPN-AC-500PC

[0269]

[0186] Example 2. Potassium (R)-1 -phenylethyl (4-chloro-1 -(4'-(1- ((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1 '-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate

[0270]

[0187] Step 1: 1-(4-bromophenyl)-N-(methylsulfonyl)cyclopropane-1 -carboxamide

[0271]

[0188] 1-(p-Bromophenyl)cyclopropanecarboxylic acid (2.41 g, 10.0 mmol) was suspended in dichloromethane (50 mL) and treated with a catalytic amount of N, N-dimethylformamide (3 drops) at room temperature. The reaction mixture was cooled to 0°C with an ice / water bath. Oxalyl chloride (1.75 mL, 20.0 mmol) was added dropwise and the resulting mixture was stirred at 0°C for 15 minutes and at room temperature for 30 minutes and then heated to reflux for 1.5 hours. An aliquot was dissolved in methanol and subjected to LCMS analysis, which indicated complete conversion to the corresponding acid chloride. The volatiles were removed under reduced pressure to yield the crude acid chloride as a white solid which was used immediately. The acid chloride (2.60 g, 10.0 mmol) was dissolved in toluene (25 mL) and treated with triethylamine (7.01 mL, 50.0 mmol) and methylsulfonamide (4.75 g, 50.0 mmol). The resulting mixture was heated to reflux for 2 hours. The reaction was cooled to room temperature and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate, washed with 1 N HCI aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude solid was triturated with diisopropyl ether and filtered. Product obtained as a tan solid. Yield = 997 mg (31%). Method 3, Rt 2.74 min. MS (ESI) m / z 318.3 - 319.8 [M + H+],

[0272]

[0189] Step 2: N-(methylsulfonyl)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-1 -carboxamide

[0273]

[0190] 1-(4-bromophenyl)-N-(methylsulfonyl)cyclopropane-1 -carboxamide [Example 2, Step 1] (997 mg, 3.13 mmol) was dissolved in 1,4-dioxane (30 mL) and treated with potassium acetate (690 mg, 7.04 mmol) and pinacol diborane (1.99 g, 7.83 mmol). The resulting mixture was degassed under N2for 10 minutes. [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(ll), complex with dichloromethane (128 mg, 0.157 mmol) was added and the resulting mixture was heated to 95°C for 16 hours. After cooling, the reaction mixture was filtered through a pad of CELITE, rinsed with ethyl acetate and concentrated. The crude residue was purified by silica-gel chromatography, eluting with a hexanes and ethyl acetate gradient. The product was obtained as a white solid, after trituration from diethyl ether. Yield = 1.00 g (88%). Method 3, Rt 2.95 min. MS (ESI) m / z 366.0 [M + H+],

[0274]

[0191] Step 3: Ethyl-2-acetyl-3-(dimethylamino)acrylate

[0275] PATENT Docket No. EPN-AC-500PC

[0276]

[0192] A mixture of ethyl acetoacetate (200.0 g, 1.54 mol) and dimethylformamide dimethyl acetal (219.7 g, 1.84 mol) was stirred at room temperature for 16 hours. Reaction was monitored by thin layer chromatography (30 % ethyl acetate in hexanes). The reaction mixture was concentrated under reduced pressure to yield 290.0 g of crude product, which was taken to the next step without further purification. Method 4, Rt 1.584 min. MS (ESI) m / z 186.00-187.00 [M + H+],

[0277]

[0193] 1H NMR (DMSO-de) 07.60 (s, 1 H); 4.13 (q, 2H); 3.34 - 2.90 (br, 6H); 2.14 (s, 3H); 1.24 (t, 3H).

[0278]

[0194] Step 4: Ethyl 1-(p-bromophenyl)-5-methyl-1 H-pyrazole-4-carboxylate

[0279]

[0195] To a solution of ethyl-2-acetyl-3-(dimethylamino)acrylate [Example 2, Step 3] (290.0 g, 1.57 mol) in ethanol (4.35 L) was added 4-bromophenyl hydrazine hydrochloride (315.0 g, 1.41 mol) at room temperature. The resulting mixture was refluxed for 3 hours. Reaction progress was monitored by thin layer chromatography (40 % ethyl acetate in hexanes). The reaction mixture was concentrated to dryness under reduced pressure to yield the crude product, which was recrystallized with 10 % of diethyl ether in hexane to yield 174.0 g of the title compound as a pale-yellow solid. The mother liquor was concentrated to dryness and recrystallized with 10 % of diethyl ether in hexane to yield another 116.0 g of product. Total yield = 290.0 g (60 %). Method 4, Rt 2.954 min. MS (ESI) m / z 309.00-310.00 [M + H+],

[0280]

[0196] 1H NMR (DMSO-de) 5 8.03 (s, 1 H); 7.78 (d, 2H); 7.53 (d, 2H); 4.26 (m, 2H); 3.34 (s, 3H); 1.30 (m, 3H).

[0281]

[0197] Step 5: 1-(p-Bromophenyl)-5-methyl-1 H-pyrazole-4-carboxylic acid

[0282]

[0198] To a solution of ethyl 1-(p-bromophenyl)-5-methyl-1 H-pyrazole-4-carboxylate [Example 2, Step 4] (200.0 g, 0.65 mol) in ethanol (1.4 L) and was added an aqueous solution of KOH (72.45 g, 1.29 mol) dissolved in water (1 L) at room temperature. The resulting mixture was refluxed for 3 hours. Reaction was monitored by thin layer chromatography (10 % methanol in chloroform). The reaction mixture was concentrated under reduced pressure to yield the corresponding potassium salt, which was dissolved in water and washed with diethyl ether. The aqueous layer was neutralized with aqueous 6N HOI solution and extracted with ethyl acetate. The organic layer was washed with water, brine then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to yield 172.0 g of product as an off-white solid (Yield = 95 %). Method 4, Rt 2.341 min. MS (ESI) m / z 280.8-280.9 [M + H+],

[0283]

[0199] 1H NMR (DMSO-de) 5 12.48 (s, 1 H); 7.99 (s, 1 H); 7.77 (d, 2H); 7.53 (d, 2H); 3.36 (s, 3H).

[0284]

[0200] Step 6: 1 -(p-Bromophenyl)-5-methyl-1 H-pyrazole

[0285] PATENT Docket No. EPN-AC-500PC

[0286]

[0201] 1-(p-Bromophenyl)-5-methyl-1 H-pyrazole-4-carboxylic acid [Example 2, Step 5] (300.0 g, 1.07 mol) was placed in a 3-liter round bottom flask and was stirred at 260 °C (bath temp 280 to 300 °C) for 10 h. Reaction was monitored by thin layer chromatography (10 % methanol in chloroform). The reaction mixture was diluted with diethyl ether and washed with 10 % of sodium carbonate, water, and brine then dried over sodium sulfate and filtered. The organic layer was concentrated under reduced pressure to yield 200.0 g of product, as a pale brown liquid (Yield-79 %). Method 4, Rt 2.739 min. MS (ESI) m / z 237.0-239.9 [M + H+],

[0287]

[0202] Step 7: 2-(p-Bromophenyl)-2H-pyrazole-3-carboxylic acid

[0288]

[0203] A solution of 1 -(p-bromophenyl)-5-methyl-1 H-pyrazole [Example 2, Step 6] (200.0 g, 0.84 mol) in tert-butanol (2 L) was treated with an aqueous solution of KOH (141.7 g, 2.53 mol) dissolved in water (1 L) at RT followed by KMnO4(266.6 g, 1.69 mol). The resulting mixture was refluxed for 3 hours then the same amount of KMnO4was added twice within a 1 -hour interval, continuing heating for 10 hours. Reaction was monitored by thin layer chromatography (10 % methanol in chloroform). The reaction mixture was filtered through a pad of Celite and washed with hot water. The aqueous solution washed with diethyl ether, then neutralized with 6N HCI solution and extracted with ethyl acetate. The organic layer was washed with water, brine then dried over sodium sulfate, filtered and concentrated under reduced pressure to yield 120.0 g of product, as a pale yellow solid (Yield = 53 %). Method 4, Rt 2.210 min. MS (ESI) m / z 269.00 [M + H+],

[0289]

[0204] 1H NMR (DMSO-d6) 6 13.40 (s, 1 H); 7.79 (s, 1 H); 7.66 (d, 2H); 7.43 (d, 2H); 7.03 (s, 1 H).

[0290]

[0205] Step 8: 3-[(R)-1-Phenylethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole

[0291]

[0206] A suspension of 2-(p-bromophenyl)-2H-pyrazole-3-carboxylic acid [Example 2, Step 7] (1.69 g, 6.36 mmol) in toluene (64 mL) was treated with triethylamine (1.07 mL, 7.63 mmol), (R)-1-phenyl-1 -ethanol (1.16 g, 9.54 mmol) and diphenylphosphoryl azide (1.94 g, 7.04 mmol) sequentially. The resulting solution was heated to 90°C for 6 hours with reaction monitoring by LCMS. The reaction was cooled to room temperature and the volatiles removed in vacuo. The crude residue was purified by silica gel chromatography, eluting with hexanes / ethyl acetate gradient. The product was obtained as a yellow oil, which solidified upon standing. Yield = 839 mg (34 %). Method 3, Rt 3.05 min. MS (ESI) m / z 388.0 [M + H+],

[0292]

[0207] Step 9: 3-[(R)-1-Phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole

[0293]

[0208] N-Chlorosuccinimide (97 mg, 0.73 mmol) was added to a stirring solution containing 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazolePATENT Docket No. EPN-AC-500PC

[0294] [Example 2, Step 8] (281 mg, 0.73 mmol) in acetonitrile (3.7 mL) at room temperature. The resulting mixture was heated to 80°C for 5 hours, after which time the reaction was deemed complete by LCMS. The reaction mixture was cooled to room temperature, concentrated in vacuo and purified directly via silica-gel column chromatography, eluting with a hexanes / ethyl acetate gradient. The product was obtained as a yellow oil, which solidified upon standing. Yield = 277 mg (91 %). Method 3, Rt 3.24 min. MS (ESI) m / z 422.1 [M + H+],

[0295]

[0209] Step 10: (R)-1 -phenylethyl (4-chloro-1-(4'-(1-((methylsulfonyl)carbamoyl)-cyclopropyl)-[1,1'-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate

[0296]

[0210] A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 2, Step 9] (210 mg, 0.5 mmol), 2:1 v / v mixture of toluene and ethanol (5 mL), 2M Na2CO3aqueous solution (1.67 mL) and N-(methylsulfonyl)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-1-carboxamide [Example 2, Step 2] (219 mg, 0.6 mmol) was degassed under N2for 10 minutes and treated with Pd[Ph3P]4(29 mg, 0.025 mmol). The resulting mixture was heated to 85°C and stirred for 16 hours at that temperature. The reaction mixture was cooled to room temperature, extracted with ethyl acetate (50 mL) and washed with 1 N HCI aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by silica-gel chromatography, eluting with a hexanes and ethyl acetate gradient. Product obtained as a white solid. Yield = 140 mg (48 %). Method 3, Rt 3.36 min. MS (ESI) m / z 579.4 [M + H+],

[0297]

[0211] Step 11: Potassium (R)-1 -phenylethyl (4-chloro-1-(4'-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1, T-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate

[0298] A suspension of (R)-1 -phenylethyl (4-chloro-1-(4'-(1-((methylsulfonyl)carbamoyl)-cyclopropyl)-[1, 1 '-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate [Example 2, Step 10] was suspended in 20% ethanol in DCM (10 vol.) at 20-30 °C. This suspension was stirred at the same temperature for 30-40 minutes to obtain a homogeneous clear solution. The solution was passed through a Polish filter into a clean vessel and washed with 20% ethanol in DCM (1 vol.). This solution was concentrated to 3-4 volumes under vacuum below 50 °C. Ethanol (2 x 4 volumes) was added and the solution distilled down to 3-4 vol. The process was repeated several times to remove DCM traces.

[0299] Potassium hydroxide (1.2 eq. based on dry weight of pure (R)-1 -phenylethyl (4-chloro-1-(4'-(1 -((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate) in polish filtered ethanol (8 vol.) was prepared at 25-35 °C in a separate vessel. The suspension was stirred for 30 minutes to get a clear solution which wasPATENT Docket No. EPN-AC-500PC

[0300] passed through a Polish filter. This solution was added to the solution of (R)-1-phenylethyl (4-chloro-1 -(4'-( 1 -((methylsulfonyl)carbamoyl)cyclopropyl)-[1, 1 '-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate at 25-30 °C and stirred for 4-5 hours. The solid suspension was filtered and washed with polish filtered ethanol (1 vol.) before drying at 55-60 °C for 32-34 hours in VTD to afford dry product as a white solid.

[0301]

[0212] LCMS Method 3, Rt 2.81 min. MS (ESI) m / z 579.3.3 [M + H+],

[0302] Example 3. (R)-1 -phenylethyl (1-(4'-(1-(1 H-tetrazol-5-yl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-4-chloro-1 H-pyrazol-5-yl)carbamate

[0303]

[0213] Step 1: 3-[(R)-1-Phenylethoxycarbonylamino]-4-chloro-2-[4'-(1-cyanocyclopropyl)-4-biphenylyl]-2H-pyrazole

[0304]

[0214] A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 2, Step 9] (210 mg, 0.5 mmol), 2:1 v / v mixture of toluene and ethanol (5 mL), 2M Na2CO3aqueous solution (1.7 mL) and 4-(1-cyanocyclopropyl)phenylboronic acid (112 mg, 0.6 mmol) was degassed under N2for 10 minutes and treated with Pd[Ph3P]4(29 mg, 0.025 mmol). The resulting mixture was heated to 85°C and stirred for 3 hours at that temperature. The reaction mixture was cooled to room temperature, extracted with ethyl acetate (50 mL) and washed with 1N HOI aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by silica-gel chromatography, eluting with a hexanes and ethyl acetate gradient. Product obtained as a white solid. Yield = 173 mg (72 %). Method 3, Rt 3.36 min. MS (ESI) m / z 483.5 [M + H+],

[0305]

[0215] Step 2: (R)-1 -phenylethyl (1 - (4'-( 1 -(1 H-tetrazol-5-yl)cyclopropyl)-[1, 1 '- bipheny l]-4-yl)-4-chloro-1 H-pyrazol-5-yl)carbamate

[0306]

[0216] A stirred solution containing 3-[(R)-1-phenylethoxycarbonylamino]-4-chloro-2-[4'-(1-cyanocyclopropyl)-4-biphenylyl]-2H-pyrazole [Example 3, Step 1] (101 mg, 0.21 mmol) in toluene (1 mL) was treated with dibutyltin(IV) oxide (58 mg, 0.23 mmol) and trimethylsilyl azide (75 pL, 0.57 mmol). The resulting mixture was heated to 100°C for 16 hours and then cooled to room temperature and concentrated in vacuo. The residue was dissolved in ethyl acetate, treated with 1 N HCI aqueous and washed with brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by C-18 reverse phase chromatography, eluting with a water and acetonitrile + 0.1% TFA gradient. Yield = 39 mg (35 %). Method 3, Rt 3.07 min. MS (ESI) m / z 526.1 [M + H+],

[0307]

[0217] Example 4: (R)-1-(2-chlorophenyl)ethyl (1-(4'-(1-(cyanocarbamoyl)cyclopropyl)-2'-fluoro-[1,1 ’-biphenyl]-4-yl)-4-fluoro- 1 H-pyrazol-5-yl)carbamate

[0308]

[0218] Step 1: 2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazole-3-carboxylic acid ethyl ester

[0309] PATENT Docket No. EPN-AC-500PC

[0310]

[0219] Ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate [Example 1, Step 2] (1.08 g, 3.68 mmol) was dissolved in acetonitrile (12 mL) and the resulting mixture was treated with glacial acetic acid (4.6 mL). To this solution, 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (Selectfluor®, 3.91 g, 11.04 mmol) was added in one portion and the resulting mixture was heated to 105 °C for 18 hours. The mixture was cooled to room temperature and the volatiles were removed in vacuo. The crude residue was loaded directly onto a silica-gel column and purified by elution with 95:5 mixture of hexanes / ethyl acetate v / v, increasing the polarity to 9:1 over time. The product was isolated as a white solid (410 mg, 1.31 mmol, 36 %) and starting material was recovered (272 mg, 0.93 mmol, 25%). For2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazole- 3-carboxylic acid ethyl ester: HPLC (254 nm): Method 3 Rt 2.97 min. MS (ESI) m / z 313.1 [M + H+],

[0311]

[0220] 1H NMR (500 MHz, CDCl3) δ 7.60 (s, 1 H); 7.58 (d, J = 9 Hz, 2 H); 7.29 (d, J = 9 Hz, 2 H); 4.30 (q, J = 7.1 Hz, 2 H); 1.28 (t, J = 7.1 Hz, 3 H).

[0312]

[0221] Step 2: (R)-1-(4'-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1 H-pyrazol-1-yl)-2-fluoro-[1,1'-biphenyl]-4-yl)cyclopropane-1 -carboxylic acid

[0313]

[0222] A stirred suspension of (R)-[2-(4-bromo-phenyl)-4-fluoro-2H-pyrazol-3-yl]-carbamic acid 1-(2-chloro-phenyl)-ethyl ester [Example 4, Step 1] (88 mg, 0.2 mmol), 2:1 v / v toluene / ethanol (2 mL), 2 M aqueous solution of Na2CO3(670 pL) and 1-[4-(dihydroxyboranyl)-3-fluorophenyl]cyclopropane-1 -carboxylic acid (45 mg, 0.20 mmol) was degassed under nitrogen for 10 minutes and treated with Pd[Ph3P]4(12 mg, 0.01 mmol). The resulting mixture was immersed in an oil bath with stirring at 90 °C for 12 hours. The reaction was cooled, transferred to a separatory funnel and diluted with ethyl acetate (50 mL). The mixture was carefully treated with 1 N aqueous HCI solution (20 mL). The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude residue was purified by preparative TLC plate (1000 pm), eluting with a 1:1 v / v hexanes / ethyl acetate mixture. The product was obtained as a white solid. Yield = 40 mg (37 %). HPLC (254 nm): Method 3, Rt 3.14 min. MS (ESI) m / z 538.3 [M + H+],

[0314]

[0223] Step 3: (R)-1-(2-chlorophenyl)ethyl (1-(4'-(1-(cyanocarbamoyl)cyclopropyl)-2'-fluoro-[1,1'-biphenyl]-4-yl)-4-fluoro-1 H-pyrazol-5-yl)carbamate

[0315]

[0224] A stirring mixture containing (R)-1-(4'-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1 H-pyrazol-1-yl)-2-fluoro-[1,1'-biphenyl]- 4-yl)cyclopropane-1 -carboxylic acid [Example 4, Step 2] (107 mg, 0.2 mmol) THF (1 mL) and N-hydroxysuccinimide (23 mg, 0.2 mmol) was treated with N, N'-dicyclohexylcarbodiimide (41 mg, 0.2 mmol) at room temperature. The resulting mixturePATENT Docket No. EPN-AC-500PC

[0316] was stirred for 3 hours, then the separated solids were filtered and the filtrate solution was added to a stirring solution of sodium hydrogen cyanamide (38 mg, 0.6 mmol) in water (1 mL). The resulting mixture was stirred for 2 days at room temperature. The reaction mixture was diluted with ethyl acetate (30 mL) and treated with 0.1 N HCI aqueous to pH ~ 3. The organic layer was separated, washed with brine, dried over anhydrous MgSCU, filtered and evaporated. The crude product was purified by preparative thin layer chromatography, eluting with a 90:10 v / v mixture of dichloromethane and methanol, respectively. Yield = 36 mg (32 %). Method 3, Rt 3.13 min. MS (ESI) m / z 561.9 [M + H+],

[0317]

[0225] Example 5: (R)-1 -phenylethyl (4-chloro-1-(4'-(1- (cyanocarbamoyl)cyclopropyl)-[1,1 '-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate

[0318]

[0226] Step 1: Methyl 1-(4'-{5-[(R)-1-phenylethoxycarbonylamino]-4-chloro-1 H-pyrazol-1-yl}-4-biphenylyl)cyclopropanecarboxylate

[0319]

[0227] A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 2, Step 9] (43 mg, 0.103 mmol), 2:1 v / v mixture of toluene and ethanol (1 mL), 2M Na2CO3aqueous solution (343 pL) and methyl 1 -[p-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxylate (40 mg, 0.134 mmol) was degassed under N2for 10 minutes and treated with Pd[Ph3P]4(6 mg, 0.052 mmol). The resulting mixture was heated to 85°C and stirred overnight at that temperature. The reaction mixture was cooled to room temperature and the product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4and filtered. After concentration in vacuo, the residue was purified by silica-gel chromatography, eluting with a hexanes / ethyl acetate gradient. Yield = 45 mg (85 %). Method 3, Rt 3.34 min. MS (ESI) m / z 516.1 [M + H+],

[0320]

[0228] Step 2: (R)-1 -(4'-(4-chloro-5-(((1 -phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-[1,1'-biphenyl]-4-yl)cyclopropane-1 -carboxylic acid

[0321]

[0229] Methyl 1-(4'-{5-[(R)-1-phenylethoxycarbonylamino]-4-chloro-1 H-pyrazol-1 -yl}-4-biphenylyl)cyclopropanecarboxylate [Example 5, Step 1] (45 mg, 0.087 mmol) was dissolved in THF (1 mL) and treated with a 1 M LiOH aqueous solution (1 mL). The resulting mixture was stirred at room temperature for 24 hours. The reaction mixture was treated with 1 M HCI aqueous in order to bring pH to 1. The product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4and filtered. After concentration in vacuo, the residue was purified by preparative thin layer chromatography on silica-gel, eluting with a 95:5 v / v dichloromethane / methanol mixture. Yield = 23 mg (53 %). Method 3, Rt 3.11 min. MS (ESI) m / z 502.3 [M + H+[.

[0322]

[0230] Step 3: (R)-1 -phenylethyl (4-chloro-1-(4'-(1-(cyanocarbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate

[0323] PATENT Docket No. EPN-AC-500PC

[0324]

[0231] (R)-1 -(4'-(4-chloro-5-(((1 -phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-[1,1 biphenyl]-4-yl)cyclopropane-1 -carboxylic acid [Example 5, Step 2] (200 mg, 0.40 mmol) was co-evaporated twice with pyridine (10 mL) and dissolved in DMF (4.5 mL). The resulting solution was treated with pyridine (300 pL, 3.75 mmol) followed by dropwise addition of pentafluorophenyl trifluoroacetate (125 pL, 0.71 mmol). After 2 hours at room temperature, LCMS analysis indicates complete conversion to the corresponding pentafluorophenyl ester. The reaction mixture was diluted with ethyl acetate (30 mL) and treated with saturated NaHCC aqueous solution. The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and evaporated. The residue was taken up in DMF (4 mL) and treated with sodium hydrogen cyanamide (77 mg, 1.2 mmol) at room temperature overnight. Next morning, reaction was diluted with ethyl acetate (30 mL) and treated with saturated NaHCO3aqueous solution. The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and evaporated. The product was purified by preparative thin layer chromatography, eluting with a 90:10 v / v mixture of dichloromethane and methanol, respectively. Yield = 36 mg (32 %). Method 3, Rt 2.84 min. MS (ESI) m / z 526.5 [M + H+],

[0325]

[0232] Example 6: Receptor Binding Assays

[0326]

[0233] Binding affinity of compounds of Formula I- VI were determined based on their ability to displace tritiated lysophosphatidic acid ([3H]-LPA) from CHO cells expressing LPAR1 in a protocol similar to that described in reference 17. In a 96 well format, CHO cells expressing human LPAR1 [Cerep] were treated with [3H]-LPA (2nM). Test compounds were added in increasing concentration to each well and incubated at room temperature for 90 minutes. At this time the plates were washed and the wells counted for radioactivity. Results were compared to a control in which cells were treated with [3H]-LPA in the presence of 10pM unlabeled LPA. The specific ligand binding to the receptors was defined as the difference between the total binding and the nonspecific binding determined in the presence of an excess of unlabeled ligand. The results were expressed as a percent of control specific binding ((measured specific binding / control specific binding) x 100) and as a percent inhibition of control specific binding (100-((measured specific binding / control specific binding) x 100)) obtained in the presence of the test compounds. The IC50 value (concentration causing a half-maximal inhibition of control specific binding) and Hill coefficient (nH) were determined by non-linear regression analysis of the competition curve generated with mean replicate values using Hill equation curve fitting (Y = D + [(A - D) / (1 + (C / C50)nH)], where Y = specific binding, D = minimum specific binding, A = maximum specific binding, C = compound concentration, C50 = IC50, and nH = slope factor). This analysis was performed using a software developed at Cerep (Hill software) and validated by comparison with data generated by the commercial

[0327] PATENT Docket No. EPN-AC-500PC

[0328] software SigmaPlot® 4.0 for Windows® (© 1997 by SPSS Inc.). The inhibition constant (Ki) was calculated using the Cheng Prusoff equation (Ki = IC50 / (1 +(L / KD)), where L = concentration of radioligand in the assay, and KD = affinity of the radioligand for the receptor). A scatchard plot was used to determine the Kd.

[0329]

[0234] Example 7: Calcium Flux Assay

[0330]

[0235] Inhibition of LPA-stimulated Ca2+flux was used to assess compound potency using FLIPR technology in a 96 well plate format. The assay buffer used was a modified Hanks Balanced Salt Solution (HBSS) where HBSS was supplemented to contain 20mM HEPES and 2.5mM Probenecid at pH7.4 (Millipore, GPCRProfiler®). LPAR1 expressing cells (Millipore) were plated and prepared 24 hours prior to assay of test articles. Ca2+ion flux was assessed from fluorescence of a Fluro-based No Wash Ca2+dye. Antagonist data are generated from plates with LPA concentrations sufficient to generate 80% efficacy [ECao]. Percentage inhibition was calculated from a reduction of efficacy according to concentration of compounds of Formula l-VI. For dose responses the inhibition data was used to calculate compound ICso. The agonist assay was conducted on a FLIPRTETRAinstrument where the test compound(s), vehicle controls, and reference agonist were added to the assay plate after a fluorescence baseline was established. The agonist assay was a total of 180 seconds and was used to assess each compound’s ability to activate each GPCR assayed. Upon completion of the agonist assay, the assay plate was removed from the FLIPRTETRAand incubated at 25°C for seven (7) minutes. After the incubation period, the assay plate was placed back in the FLIPRTETRAand the antagonist assay was initiated.

[0331]

[0236] Antagonist Assay: Using ECso potency values determined during the agonist assay, all pre-incubated sample compound wells were challenged with ECso concentration of reference agonist after establishment of a fluorescence baseline. The antagonist assay was conducted using the same assay plate that was used for the agonist assay. The antagonist assay was conducted on a FLIPRTETRAinstrument where 9 vehicle controls and ECso concentration of reference agonist were added to appropriate wells. The antagonist assay was a total of 180 seconds and was used to assess each compound’s ability to inhibit each GPCR assayed.

[0332]

[0237] Data Processing: All assay plate data were subjected to appropriate baseline corrections. After baseline corrections were applied, maximum fluorescence values were exported and data processed to calculate percentage activation (relative to Emax reference agonist and vehicle control values), percentage inhibition (relative to EC80 and vehicle control values), and additional statistical values (i.e., Z’, percentage variation between replicate data values) to assess the quality of each plate. WherePATENT Docket No. EPN-AC-500PC

[0333] assay plate data were rejected, additional experiments were conducted. All dose response curves were generated using GraphPad Prism. The curves were fit by utilizing “Sigmoidal Dose Response (Variable Slope)” equation where the bottom parameter was fixed to “0.” Where appropriate, the top parameter was fixed to “100” to better predict potency values when a full curve was not generated by the concentrations assayed.

[0334]

[0238] Antagonist activity data for representative compounds prepared according to the synthetic methods disclosed herein are presented in Table 1.

[0335]

[0239] Table 1. In vitro biological data for representative compounds of Formula I Unless otherwise noted, compounds that were tested had an I C5o of less than 50 pM in the LPA1 R Ca2+flux functional assay.

[0336]

[0337]

[0240] Unless otherwise noted, compounds that were tested had an IC50 of less than 50 pM in the LPA1 R Ca2+flux functional assay. A = less than 0.3 pM; B = greater than 0.3 pM and less than 1 pM; C = greater than 1 pM and less than 50 pM; D = greater than 50 pM

[0338]

[0241] Example 8: Effect of test compounds on MCP-1 stimulated RAW264.7 cell migration

[0339]

[0242] A stock solution of compound (1 OpM) was diluted 50-fold with PBS to the final concentration to be used in the migration assay. For the migration assay, briefly, each test solution (1 pL) was diluted 50-fold in RAW264.7 cell suspension (49 pL). Final concentrations in a dose range of 10 fM to 10 pM were tested. MCP-1 solution (108M, 26 pL) was added to the bottom chamber of the Boyden apparatus. A 5-micron polycarbonate membrane was applied, followed by the gasket and the donor chamber apparatus screwed into place. Once assembled, positive controls and test wells (compound plus cell incubations), all ~50 pL, were pipetted into the upper chamber. A set of background wells was established with a bottom chamber containing MEM only and the upper wells RAW264.7 cells (50 pL). Once complete, the setup is incubated at 35°C for 1 hour. After 1 hour, the apparatus was disassembled and inverted to allow for the removal of the upper chamber and gasket. The filter was clamped, and the

[0340] PATENT Docket No. EPN-AC-500PC

[0341] underside was rinsed and scraped in PBS before fixing it in methanol and drying on a glass slide. The dried filter was hematoxylin and eosin stained, and cells were visualized by microscope. Cell count was determined for each well as the average of 5 fields under the microscope. Cell counts for the positive control (no antagonist) and test wells were corrected for background by subtraction of any cells counted on the membrane in the negative control (no MCP-1 in the receiving chamber).

[0342]

[0243] Percent inhibition of migration was determined by (Cell count in test wells) x 100 / (Cellcount in positive control)

[0343]

[0244] Example 9: Effect of test compounds on human stellate cell proliferation

[0344]

[0245] HSCs were isolated as previously described. [Yoshida 2014, Schwabe 2003], DMEM, fetal calf serum, antimycotic / antibiotic, Cyquant cell proliferation kit, and Ca2+ / Mg2+-free PBS were from Thermofisher (Waltham, MA). OleoylLPA-sodium salt was from Cayman Chemicals (Ann Arbor, Ml). Thirty percent fatty acid-free bovine serum albumin was purchased from Sigma (St. Louis, MO). LPA was dissolved in Ca2+ / Mg2+-free PBS containing 0.1% fatty acid-free bovine serum albumin to give a 1 mM stock solution. The solution was sonicated for 15 minutes (min) before use. Test compounds were diluted from a 10 pM solution in DMSO. HSCs were thawed and cultured in high glucose DMEM with 10% fetal calf serum and antibiotic / antimycotic at 37°C, 5% CO2. Cells were used between passages 4 and 7. Cells were plated at 1000 or 2000 cells / well of a 96-well plate and incubated overnight. The following day media was replaced with that containing 0.5% fetal bovine serum (FBS) for 24 h. The following day media was replaced with 100 pl media containing 0.5% FBS and 0.1 % DMSO or compound at 1 pM, 0.1 pM or 0.01 pM for 15 min, followed by the addition of a further

[0345] 10OpI media containing 0.5% FBS, vehicle, 20 pM LPA (2x final concentration) and / or 1 pM, 0.1 pM, 0.01 pM compound. Cells were incubated for 48 hours before removing the media and freezing the plate at -80°C overnight. According to the manufacturer’s instructions, the relative cell number per well was assessed using the Cyquant cell proliferation kit. Fluorescence was determined using a Clariostar™ plate reader.

[0346]

[0246] Example 10: Pharmacokinetic analysis of test compounds

[0347]

[0247] Compound solution was prepared fresh in a vehicle formulation of 20% Solutol and 40% PEG400 in 40% water at a 5 mg / mL concentration. Female CD1 mice were acclimatized to living conditions and then divided into groups of 3 animals each / time point. Compound was administered by oral gavage (dose 20 mg / kg). Plasma samples were diluted with blank mouse plasma as needed. An aliquot of 20 pL of plasma sample was extracted with 100 pL of acetonitrile containing internal standard (terfenadine). The mixture was vortexed on a shaker for 15 minutes and subsequently centrifuged at 4000PATENT Docket No. EPN-AC-500PC

[0348] rpm for 15 minutes. An aliquot of 70 pL of the supernatant was mixed with 70 pL of water for the injection into the LC / MS / MS [Shimadzu LC30AD: Waters Acquity UPLC BEH C18, 50 x 2.1 mm, 1,7pM; Mobile phases: A: water with 0.1% formic acid; B: acetonitrile with 0.1% formic acid.]. Calibration standards and quality control samples were prepared by spiking the test compound into blank mouse plasma and then processed with the unknown samples.

[0349]

[0248] Statistical Analysis: Statistical comparison between the experimental groups was performed using one-way or two-way ANOVA and post hoc Bonferroni test. Student t test was used to determine a statistical comparison between the 2 experimental groups. The p-value of <0.05 was considered statistically significant. Results were presented as mean ± SEM.

[0350]

[0249] Example 11: Activity of Example 2 (Ex.2) in the ARE del / _mouse pre-clinical model of PBC.

[0351]

[0250] Example 2 was formulated in 0.5% HPMC, 0.1% Tween 80 in DI water to a concentration of 5 mg / mL and assessed in the ARE del / _pre-clinical model of PBC, the most representative PBC model currently reported (Bae 2018, Bae 2016, Hodge 2014). Ex.2 was administered after animals had been established as described (Bae 2018, Bae 2016, Hodge 2014) at 12 weeks and compared to a vehicle control. The study design is shown in Figure 4. Vehicle was compared to a low (L) dose of 10mg / Kg / day or a high (H) dose of 20mg / Kg / day. At 24 weeks, animals were sacrificed and histopathologic analysis of H& E stained livers conducted.

[0352]

[0251] Histopathological Analyses: H& E stained livers were assessed for pathological score (scale 1-5).

[0353]

[0252] Results: Example 2 demonstrated statistical improvements in preventing bile duct damage (p < 0.05: Figure 5) at both low and high doses. Reductions in portal inflammation for Ex. 2 was significant (p < 0.05: Figure 5) compared to the low dose (p < 0.07). A dose dependent reduction in inflammation was evident.

[0354] CITATIONS

[0355] 1 Yoshida S, Ikenaga N, Liu SB, Peng ZW, Chung J, Sverdlov DY, et al. Extrahepatic platelet-derived growth factor-p, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology. 2014;147: 1378- 92.

[0356] 2 Schwabe RF, Dataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTESto induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol [Internet], 2003:285: G949-58.

[0357] PATENT Docket No. EPN-AC-500PC

[0358] 3 Bae HR, Hodge DL, Yang GX, Leung PSC, Chodisetti SB, Valencia JC, Sanford M, Fenimore JM, Rahman ZSM, Tsuneyama K, Norman GL, Gershwin ME, Young HA. (2018). The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity. Hepatology.; 67(4):1408-1419.

[0359] 4 Bae HR, Leung PS, Tsuneyama K, Valencia JC, Hodge DL, Kim S, BackT, Karwan

[0360] M, Merchant AS, Baba N, Feng D, Park O, Gao B, Yang G-X, Gershwin ME, Young HA. (2016). Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology 64(4):1189-201.

[0361] 5 Hodge DL, Berthet C, Coppola V, Kastenmuller W, Buschman MD, Schaughency PM, Shirota H, Scarzello AJ, Subleski JJ, Anver MR, Ortaldo JR, Lin F, Reynolds DA, Sanford ME, Kaldis P, Tessarollo L, Klinman DM, Young HA. (2014). IFN- gamma AU -rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice. Journal of autoimmunity; 53:33-45. 13.

Claims

PATENT Docket No. EPN-AC-500PCCLAIMSWhat is claimed is:

1. A method of treatment of a cholangiopathy comprising administrating an effective amound of a lysophosphatidic acid receptor subtype 1 (LPAR1) antagonist to a subject in need thereof.

2. The method of claim 1 the cholangiopathy is selected from the group consisting of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and biliary atresia (BA).

3. The method of claim 1 wherein the cholangiopathy is primary biliary cholangitis (PBC).

4. The method of any one of claims 1 -3, wherein the LPAR1 antagonist is a compound of formula I having the structure of:Formula Ior a salt thereof,wherein RAis -CO2H, -CO2RB, -CN, tetrazolyl, -C(=O)NH2>-C(=O)NHRB,wherein RBis unsubstituted or substituted C1-C4 alkyl or has the structure of oneof:, andL1is substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted Ci- Csfluoroalkylene, substituted or unsubstituted C3-C8cycloalkylene, substituted or unsubstituted Ci-C3heteroalkylene, in particular, L1is cyloprop-1,1 -di-yl;A1is -N= or -CH=;PATENT Docket No. EPN-AC-500PCRing A has the structure of:wherein Rcis -CN, -F, -Cl, -Br, -I, -OC1-C4 alkyl, Cs-Ce cycloalkyl, or C1-C4 fluoroalkyl;and RDis -N(RF)-C(=O)XCH(RG)-CY, wherein X is O and CY is phenyl substituted with one RHso that RDhas the structure of:RE, RFand RGindependently are -H or C1-C4 alkyl or C3-C6cycloalkyl or REand RFindependently are -H or C1-C4 alkyl or Ci-C3cycloalkyl and RGis -C1-C4 alkyl and is taken together with the unsubstituted or RHsubstituted pheny moiety of RDand the carbon atom to which RGand said phenyl moiety is attached to define a substituted or unsubstituted C4-C7 carbocycle or a substituted or unsubstituted C4- C7heterocycle fused to said RDpheny moiety;RHis absent so that the RDphenyl moiety is unsubstituted or RHis halogen, -CN, -NO2, -OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, or C1-C4 alkoxy.

5. The method of claim 1, wherein the LPAR1 antagonist is selected from the group consisting of (R)-1 -(4'-{5-[1 -(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro- pyrazol-1 -yl}-3-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1 - (4'-{5-[ 1 - (2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl- 4-yl)-cyclopropanecarboxylic acid, (R)-1 - (2-Ch loro-4'-{5- [1 -(2-chloro-phenyl)- ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)- ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-methyl-biphenyl-4-yl)- cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)- ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid, (R)- 1-{4'-[5-(1-Phenyl-ethoxycarbonylamino)-4-PATENT Docket No. EPN-AC-500PCtrifluoromethyl-pyrazol-1 -yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, (R)-1 -{2- Fluoro-4'-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid, (R) - 1 - (4-{5-[5-( 1 -Phenyl- ethoxycarbonylamino)-pyrazol-1-yl]-pyridin-2-yl}-phenyl) -cyclopropanecarboxylic acid, (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1 H- pyrazol-1 -yl)pyridin-2-yl)phenyl)cyclopropane-1 -carboxylic acid, (R)-1 -(4-(5-(4- chloro-5-(((1 -(2-chlorophenyl)ethoxy)carbonyl)amino)-1 H-pyrazol-1 -y I) py ridin-2- yl)phenyl)cyclopropane-1 -carboxylic acid, (R)-1 -(4'-(4-fluoro-5-(((1 - phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-[1,1 '-biphenyl]-4- yl)cyclopropane-1 -carboxylic acid, (R)-1-(4'-(4-chloro-5-(((1- phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-[1,1 '-biphenyl]-4- yl)cyclopropane-1 -carboxylic acid, (R)-1 -(3-fluoro-4’-(4-fluoro-5-(((1 - phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-[1,1 '-biphenyl]-4- yl)cyclopropane-1 -carboxylic acid, (R)-1 -(2-fluoro-4’-(4-fluoro-5-(((1 - phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-[1,1 ’-biphenyl]-4- yl)cyclopropane-1 -carboxylic acid, (R)-1-(4'-(4-chloro-5-(((1- phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-3-fluoro-[1,1'-biphenyl]-4- yl)cyclopropane-1 -carboxylic acid, (R)-1-(4'-(4-chloro-5-(((1- phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-2-fluoro-[1,1'-biphenyl]-4- yl)cyclopropane-1 -carboxylic acid, (R)-1 -(2-chloro-4'-(4-fluoro-5-(((1 - phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-[1,1 '-biphenyl]-4- yl)cyclopropane-1 -carboxylic acid, (R)-1-(2-chloro-4'-(4-chloro-5-(((1- phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-[1,1 '-biphenyl]-4- yl)cyclopropane-1 -carboxylic acid, (R)-1-(4'-(4-fluoro-5-(((1- phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-2-methyl-[1,1 '-biphenyl]-4- yl)cyclopropane-1 -carboxylic acid, (R)-1-(4'-(4-chloro-5-(((1- phenylethoxy)carbonyl)amino)-1 H-pyrazol-1 -yl)-2-methyl-[1,1 '-biphenyl]-4- yl)cyclopropane-1 -carboxylic acid, (R)-1-(2-chlorophenyl)ethyl (1 -(4'-(1 - carbamoylcyclopropyl)-[1,1 '-biphenyl]-4-yl)-4-fluoro-1 H-pyrazol-5-yl)carbamate, (R)-1 -(2-chlorophenyl)ethyl (4-fluoro-1 -(2'-f I uoro-4'-(1 - ((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1 H-pyrazol-5- yl)carbamate, (R)-1 -phenylethyl (4-fluoro-1-(2'-fluoro-4'-(1- ((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1 H-pyrazol-5- yl)carbamate, (R)-1 -(2-chlorophenyl)ethyl (4-chloro-1 -(2'-f luoro-4'-( 1 - ((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1 '-biphenyl]-4-yl)-1 H-pyrazol-5- yl)carbamate, (R)-1 -phenylethyl (4-chloro-1-(4'-(1- ((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1 '-biphenyl]-4-yl)-1 H-pyrazol-5-PATENT Docket No. EPN-AC-500PCyl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(4'-(1- ((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1'-biphenyl]-4-yl)-1 H-pyrazol-5- yl)carbamate, (R)-1 -(2-chlorophenyl)ethyl (1 -(4'-(1 -(1 H-tetrazol-5-yl)cyclopropyl)- [1,1'-biphenyl]-4-yl)-4-fluoro-1 H-pyrazol-5-yl)carbamate, (R)-1 -phenylethyl (1 -(4'- (1 -(1 H-tetrazol-5-yl)cyclopropyl)-[1, 1 '-biphenyl]-4-y I) -4-ch loro- 1 H-pyrazol-5- yl)carbamate, (R)-1 -(2-chlorophenyl)ethyl (1 -(4'-(1 -(1 H-tetrazol-5-yl)cyclopropyl)- [1,1'-biphenyl]-4-yl)-4-chloro-1 H-pyrazol-5-yl)carbamate, 3-[(R)-1 - Phenylethoxycarbonylamino]-4-chloro-2-{4'-[1- (cyanoamino)carbonylcyclopropyl]-4-biphenylyl}-2H-pyrazole, 3-[(R)-1-(o- Chlorophenyl)ethoxycarbonylamino]-4-chloro-2-{4'-[1- (cyanoamino)carbonylcyclopropyl]-4-biphenylyl}-2H-pyrazole, 3-[(R)-1-(o- Chlorophenyl)ethoxycarbonylamino]-2-{4'-[1-(cyanoamino)carbonylcyclopropyl]- 2'-fluoro-4-biphenylyl}-4-fluoro-2H-pyrazole and salts thereof.

6. The method of claim 1, wherein the LPAR1 antagonist is selected from the group consisting of (R)-1 -(4'-{5-[1 -(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro- pyrazol-1 -yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1 - phenylethyl (4-chloro-1 -(4'-(1 -((methylsulfonyl)carbamoyl)cyclopropyl)-[1, 1 '- biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate, and salts thereof.

7. The method of claim 1, wherein the selective LPAR1 antagonist is (R)-1- phenylethyl(4-chloro-1-(4'-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1, T- biphenyl]-4-yl)-1 H-pyrazol-5-yl)carbamate or a salt thereof.

8. A kit comprising a package containing a first pharmaceutically acceptable formulation comprising an effective amount of a lysophosphatidic acid receptor subtype 1 (LPAR1) antagonist and a package insert or label affixed to the package that indicates the first pharmaceutical formulation is to be administered to a subject having a cholangiopathy.

9. The kit of claim 8 wherein the LPAR1 antagonist is (R)-1 -phenylethyl (4-chloro- -((methylsulfonyl)carbamoyl)cyclopropyl)-[1, 1 '-biphenyl] -4-yl) - 1 H-pyrazol- 5-yl)carbamate or a pharmaceutically acceptable salt thereof.

10. The kit of claim 8 or 9 wherein the cholangiopathy is primary biliary cholangitis (PBC).